WO1999031052A1 - Nouveaux inhibiteurs de metalloproteinases - Google Patents
Nouveaux inhibiteurs de metalloproteinases Download PDFInfo
- Publication number
- WO1999031052A1 WO1999031052A1 PCT/JP1998/005620 JP9805620W WO9931052A1 WO 1999031052 A1 WO1999031052 A1 WO 1999031052A1 JP 9805620 W JP9805620 W JP 9805620W WO 9931052 A1 WO9931052 A1 WO 9931052A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituted
- protected
- compound
- amino
- Prior art date
Links
- 239000003475 metalloproteinase inhibitor Substances 0.000 title abstract description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 439
- -1 hydroxy, amino Chemical group 0.000 claims abstract description 288
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 154
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 93
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 76
- 239000001257 hydrogen Substances 0.000 claims abstract description 73
- 150000003839 salts Chemical class 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 44
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 15
- 238000004519 manufacturing process Methods 0.000 claims description 233
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 79
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 70
- 125000003277 amino group Chemical group 0.000 claims description 45
- 239000002253 acid Substances 0.000 claims description 42
- 125000006239 protecting group Chemical group 0.000 claims description 39
- 150000002431 hydrogen Chemical class 0.000 claims description 37
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 36
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 34
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 32
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 32
- 239000012453 solvate Substances 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 26
- 102000035195 Peptidases Human genes 0.000 claims description 24
- 108091005804 Peptidases Proteins 0.000 claims description 24
- 235000019833 protease Nutrition 0.000 claims description 24
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 21
- 201000010099 disease Diseases 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 20
- 125000001424 substituent group Chemical group 0.000 claims description 20
- 102000004190 Enzymes Human genes 0.000 claims description 19
- 108090000790 Enzymes Proteins 0.000 claims description 19
- 125000002947 alkylene group Chemical group 0.000 claims description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 19
- 125000000623 heterocyclic group Chemical group 0.000 claims description 17
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 16
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 15
- 150000002148 esters Chemical class 0.000 claims description 15
- 239000011159 matrix material Substances 0.000 claims description 13
- 239000006187 pill Substances 0.000 claims description 13
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 12
- 239000003112 inhibitor Substances 0.000 claims description 12
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 11
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- 150000001412 amines Chemical class 0.000 claims description 10
- 125000000524 functional group Chemical group 0.000 claims description 10
- 125000003107 substituted aryl group Chemical group 0.000 claims description 9
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 8
- 150000003443 succinic acid derivatives Chemical class 0.000 claims description 8
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 claims description 7
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 7
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 7
- 238000006467 substitution reaction Methods 0.000 claims description 7
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 230000008354 tissue degradation Effects 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 5
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 claims description 4
- 239000005541 ACE inhibitor Substances 0.000 claims description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 4
- 239000011593 sulfur Substances 0.000 claims description 4
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 claims description 4
- COMOEDSRBFJHCS-UHFFFAOYSA-N 1-nitroprop-1-enylbenzene Chemical group CC=C([N+]([O-])=O)C1=CC=CC=C1 COMOEDSRBFJHCS-UHFFFAOYSA-N 0.000 claims description 3
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 3
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims description 3
- 125000002757 morpholinyl group Chemical group 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims description 3
- 125000004344 phenylpropyl group Chemical group 0.000 claims description 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 3
- 125000005650 substituted phenylene group Chemical group 0.000 claims description 3
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 claims description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 2
- WBTCPVUCKKBWBS-UHFFFAOYSA-N azetidine-2,4-dione Chemical compound O=C1CC(=O)N1 WBTCPVUCKKBWBS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000002946 cyanobenzyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 claims description 2
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N 1,4-Benzenediol Natural products OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 claims 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
- DYUQAZSOFZSPHD-UHFFFAOYSA-N Phenylpropanol Chemical group CCC(O)C1=CC=CC=C1 DYUQAZSOFZSPHD-UHFFFAOYSA-N 0.000 claims 1
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims 1
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract description 34
- 230000002401 inhibitory effect Effects 0.000 abstract description 30
- 238000001727 in vivo Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 5
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 102000005741 Metalloproteases Human genes 0.000 abstract 1
- 108010006035 Metalloproteases Proteins 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 290
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 285
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 177
- 239000007787 solid Substances 0.000 description 116
- 238000005481 NMR spectroscopy Methods 0.000 description 113
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 109
- 238000006243 chemical reaction Methods 0.000 description 102
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 85
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 79
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 77
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 76
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 75
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- 235000011054 acetic acid Nutrition 0.000 description 67
- 150000001408 amides Chemical class 0.000 description 63
- 229910052799 carbon Inorganic materials 0.000 description 62
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 56
- 239000004472 Lysine Substances 0.000 description 53
- MGJXBDMLVWIYOQ-UHFFFAOYSA-N methylazanide Chemical compound [NH-]C MGJXBDMLVWIYOQ-UHFFFAOYSA-N 0.000 description 52
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 50
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 50
- 239000002904 solvent Substances 0.000 description 48
- 125000003118 aryl group Chemical group 0.000 description 47
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 45
- 235000019441 ethanol Nutrition 0.000 description 45
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 42
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 42
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 38
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- 230000035484 reaction time Effects 0.000 description 36
- 238000002844 melting Methods 0.000 description 32
- 230000008018 melting Effects 0.000 description 32
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 31
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 31
- 239000004744 fabric Substances 0.000 description 30
- 239000007810 chemical reaction solvent Substances 0.000 description 29
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 25
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 25
- 235000018977 lysine Nutrition 0.000 description 25
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 23
- 150000002170 ethers Chemical class 0.000 description 23
- 229920006395 saturated elastomer Polymers 0.000 description 23
- 239000002585 base Substances 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 239000007858 starting material Substances 0.000 description 22
- 239000003960 organic solvent Substances 0.000 description 20
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 19
- 229940088598 enzyme Drugs 0.000 description 18
- 239000012046 mixed solvent Substances 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- 235000019766 L-Lysine Nutrition 0.000 description 17
- 239000000741 silica gel Substances 0.000 description 17
- 229910002027 silica gel Inorganic materials 0.000 description 17
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 16
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 16
- VJMAITQRABEEKP-UHFFFAOYSA-N [6-(phenylmethoxymethyl)-1,4-dioxan-2-yl]methyl acetate Chemical class O1C(COC(=O)C)COCC1COCC1=CC=CC=C1 VJMAITQRABEEKP-UHFFFAOYSA-N 0.000 description 16
- 150000001298 alcohols Chemical class 0.000 description 16
- 238000005984 hydrogenation reaction Methods 0.000 description 16
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 16
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229940125904 compound 1 Drugs 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 150000008282 halocarbons Chemical class 0.000 description 15
- 238000003786 synthesis reaction Methods 0.000 description 15
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 239000012230 colorless oil Substances 0.000 description 14
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- BHELIUBJHYAEDK-OAIUPTLZSA-N Aspoxicillin Chemical group C1([C@H](C(=O)N[C@@H]2C(N3[C@H](C(C)(C)S[C@@H]32)C(O)=O)=O)NC(=O)[C@H](N)CC(=O)NC)=CC=C(O)C=C1 BHELIUBJHYAEDK-OAIUPTLZSA-N 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 13
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- 206010040943 Skin Ulcer Diseases 0.000 description 12
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 12
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 12
- 229940125782 compound 2 Drugs 0.000 description 12
- 238000001035 drying Methods 0.000 description 12
- 229960005190 phenylalanine Drugs 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 231100000019 skin ulcer Toxicity 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 11
- 238000005259 measurement Methods 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 239000004475 Arginine Substances 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 10
- 235000009697 arginine Nutrition 0.000 description 10
- 238000004440 column chromatography Methods 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 229960001153 serine Drugs 0.000 description 10
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 9
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 9
- 229940125898 compound 5 Drugs 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 150000005690 diesters Chemical class 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 125000005640 glucopyranosyl group Chemical group 0.000 description 9
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 229930195734 saturated hydrocarbon Natural products 0.000 description 9
- 239000003826 tablet Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 8
- 229910052783 alkali metal Inorganic materials 0.000 description 8
- 150000001340 alkali metals Chemical class 0.000 description 8
- 125000006295 amino methylene group Chemical group [H]N(*)C([H])([H])* 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 8
- 229910052697 platinum Inorganic materials 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- 235000010724 Wisteria floribunda Nutrition 0.000 description 7
- 229940126142 compound 16 Drugs 0.000 description 7
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 6
- FDSHZORMVSUDBC-SECBINFHSA-N (2R)-2-(2-methylpropyl)hexanoic acid Chemical compound CCCC[C@H](CC(C)C)C(O)=O FDSHZORMVSUDBC-SECBINFHSA-N 0.000 description 6
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 6
- 229940126657 Compound 17 Drugs 0.000 description 6
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 6
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 6
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 159000000000 sodium salts Chemical class 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 5
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 5
- 244000303965 Cyamopsis psoralioides Species 0.000 description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 208000001132 Osteoporosis Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 229940125878 compound 36 Drugs 0.000 description 5
- 239000008120 corn starch Substances 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- ZUSSTQCWRDLYJA-UHFFFAOYSA-N n-hydroxy-5-norbornene-2,3-dicarboximide Chemical compound C1=CC2CC1C1C2C(=O)N(O)C1=O ZUSSTQCWRDLYJA-UHFFFAOYSA-N 0.000 description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 235000011121 sodium hydroxide Nutrition 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 239000006188 syrup Substances 0.000 description 5
- 235000020357 syrup Nutrition 0.000 description 5
- 125000005270 trialkylamine group Chemical group 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- 239000002435 venom Substances 0.000 description 5
- 231100000611 venom Toxicity 0.000 description 5
- 210000001048 venom Anatomy 0.000 description 5
- QWUWMCYKGHVNAV-UHFFFAOYSA-N 1,2-dihydrostilbene Chemical group C=1C=CC=CC=1CCC1=CC=CC=C1 QWUWMCYKGHVNAV-UHFFFAOYSA-N 0.000 description 4
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 4
- KPWDGTGXUYRARH-UHFFFAOYSA-N 2,2,2-trichloroethanol Chemical compound OCC(Cl)(Cl)Cl KPWDGTGXUYRARH-UHFFFAOYSA-N 0.000 description 4
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 4
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108060005980 Collagenase Proteins 0.000 description 4
- 102000029816 Collagenase Human genes 0.000 description 4
- 235000003332 Ilex aquifolium Nutrition 0.000 description 4
- 241000209027 Ilex aquifolium Species 0.000 description 4
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 159000000021 acetate salts Chemical class 0.000 description 4
- 125000000783 acetimidoyl group Chemical group C(C)(=N)* 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 229960002424 collagenase Drugs 0.000 description 4
- 229940125846 compound 25 Drugs 0.000 description 4
- 229940125851 compound 27 Drugs 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000007257 deesterification reaction Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 4
- RPDAUEIUDPHABB-UHFFFAOYSA-N potassium ethoxide Chemical compound [K+].CC[O-] RPDAUEIUDPHABB-UHFFFAOYSA-N 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- 235000017550 sodium carbonate Nutrition 0.000 description 4
- RCOSUMRTSQULBK-UHFFFAOYSA-N sodium;propan-1-olate Chemical compound [Na+].CCC[O-] RCOSUMRTSQULBK-UHFFFAOYSA-N 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 3
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 3
- GNAKABFIXDKLCV-MRVPVSSYSA-N (2R)-2-propan-2-ylhexanoic acid Chemical compound CCCC[C@H](C(C)C)C(O)=O GNAKABFIXDKLCV-MRVPVSSYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- PIYZBBVETVKTQT-ZCFIWIBFSA-N (2r)-2-(2-methylpropyl)butanedioic acid Chemical compound CC(C)C[C@@H](C(O)=O)CC(O)=O PIYZBBVETVKTQT-ZCFIWIBFSA-N 0.000 description 3
- BVRKOQJETMBIDK-VIFPVBQESA-N (2s)-2-amino-n-methyl-3-phenylpropanamide Chemical compound CNC(=O)[C@@H](N)CC1=CC=CC=C1 BVRKOQJETMBIDK-VIFPVBQESA-N 0.000 description 3
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 3
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 3
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 3
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 3
- NYSXWUPVOCFRSE-UHFFFAOYSA-N 1-phenyl-ethene-1,2-diol Natural products OC=C(O)C1=CC=CC=C1 NYSXWUPVOCFRSE-UHFFFAOYSA-N 0.000 description 3
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- ZWVHTXAYIKBMEE-UHFFFAOYSA-N 2-hydroxyacetophenone Chemical compound OCC(=O)C1=CC=CC=C1 ZWVHTXAYIKBMEE-UHFFFAOYSA-N 0.000 description 3
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 3
- UIADWSXPNFQQCZ-UHFFFAOYSA-N 4-[4-(3,4-dichlorophenyl)-5-phenyl-1,3-oxazol-2-yl]butanoic acid Chemical compound ClC=1C=C(C=CC=1Cl)C=1N=C(OC=1C1=CC=CC=C1)CCCC(=O)O UIADWSXPNFQQCZ-UHFFFAOYSA-N 0.000 description 3
- FJNCXZZQNBKEJT-UHFFFAOYSA-N 8beta-hydroxymarrubiin Natural products O1C(=O)C2(C)CCCC3(C)C2C1CC(C)(O)C3(O)CCC=1C=COC=1 FJNCXZZQNBKEJT-UHFFFAOYSA-N 0.000 description 3
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 229930186147 Cephalosporin Natural products 0.000 description 3
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 229930064664 L-arginine Natural products 0.000 description 3
- 235000014852 L-arginine Nutrition 0.000 description 3
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241001024304 Mino Species 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 208000018737 Parkinson disease Diseases 0.000 description 3
- 241000721454 Pemphigus Species 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 208000004210 Pressure Ulcer Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 235000011941 Tilia x europaea Nutrition 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 206010046851 Uveitis Diseases 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 3
- DDQAGDLHARKUFX-UHFFFAOYSA-N acetic acid;methanamine Chemical compound [NH3+]C.CC([O-])=O DDQAGDLHARKUFX-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 3
- 150000008046 alkali metal hydrides Chemical class 0.000 description 3
- 150000001350 alkyl halides Chemical class 0.000 description 3
- 208000007502 anemia Diseases 0.000 description 3
- 208000002399 aphthous stomatitis Diseases 0.000 description 3
- 208000011775 arteriosclerosis disease Diseases 0.000 description 3
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 3
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 208000020670 canker sore Diseases 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 229940124587 cephalosporin Drugs 0.000 description 3
- 150000001780 cephalosporins Chemical class 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125810 compound 20 Drugs 0.000 description 3
- 229940125961 compound 24 Drugs 0.000 description 3
- 229940125877 compound 31 Drugs 0.000 description 3
- 229940125936 compound 42 Drugs 0.000 description 3
- 229940125844 compound 46 Drugs 0.000 description 3
- 201000007717 corneal ulcer Diseases 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 210000002950 fibroblast Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 150000007529 inorganic bases Chemical class 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 229960004592 isopropanol Drugs 0.000 description 3
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 3
- 239000004571 lime Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 201000004792 malaria Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- MKQLBNJQQZRQJU-UHFFFAOYSA-N morpholin-4-amine Chemical compound NN1CCOCC1 MKQLBNJQQZRQJU-UHFFFAOYSA-N 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 230000000414 obstructive effect Effects 0.000 description 3
- 150000007530 organic bases Chemical class 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000010647 peptide synthesis reaction Methods 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- 201000000980 schizophrenia Diseases 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 229960005349 sulfur Drugs 0.000 description 3
- 235000001508 sulfur Nutrition 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 2
- OBCGFTBIKFMWRW-JTQLQIEISA-N (2S)-2-(cyanoamino)-N-methyl-3-phenylpropanamide Chemical compound CNC([C@@H](NC#N)CC1=CC=CC=C1)=O OBCGFTBIKFMWRW-JTQLQIEISA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- JQTFIXBEJDHEFQ-WUBHUQEYSA-N (2r)-3-[(2-methylpropan-2-yl)oxycarbonyl]-6-[4-(phenylmethoxycarbonylaminomethyl)phenyl]-2-propan-2-ylhexanoic acid Chemical compound C1=CC(CCCC([C@@H](C(C)C)C(O)=O)C(=O)OC(C)(C)C)=CC=C1CNC(=O)OCC1=CC=CC=C1 JQTFIXBEJDHEFQ-WUBHUQEYSA-N 0.000 description 2
- FEBXYEHEYKOKMY-MIHMCVIASA-N (2r)-4-methyl-2-[1-[(2-methylpropan-2-yl)oxy]-1-oxo-3-[4-(phenylmethoxycarbonylaminomethyl)phenyl]propan-2-yl]pentanoic acid Chemical compound C1=CC(CC([C@@H](CC(C)C)C(O)=O)C(=O)OC(C)(C)C)=CC=C1CNC(=O)OCC1=CC=CC=C1 FEBXYEHEYKOKMY-MIHMCVIASA-N 0.000 description 2
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 description 2
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 2
- PFEZQIWIVSFGSC-LURJTMIESA-N (2s)-2-hydroxy-5-methylhexanoic acid Chemical compound CC(C)CC[C@H](O)C(O)=O PFEZQIWIVSFGSC-LURJTMIESA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 2
- STPKWKPURVSAJF-LJEWAXOPSA-N (4r,5r)-5-[4-[[4-(1-aza-4-azoniabicyclo[2.2.2]octan-4-ylmethyl)phenyl]methoxy]phenyl]-3,3-dibutyl-7-(dimethylamino)-1,1-dioxo-4,5-dihydro-2h-1$l^{6}-benzothiepin-4-ol Chemical compound O[C@H]1C(CCCC)(CCCC)CS(=O)(=O)C2=CC=C(N(C)C)C=C2[C@H]1C(C=C1)=CC=C1OCC(C=C1)=CC=C1C[N+]1(CC2)CCN2CC1 STPKWKPURVSAJF-LJEWAXOPSA-N 0.000 description 2
- VUEGYUOUAAVYAS-JGGQBBKZSA-N (6ar,9s,10ar)-9-(dimethylsulfamoylamino)-7-methyl-6,6a,8,9,10,10a-hexahydro-4h-indolo[4,3-fg]quinoline Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NS(=O)(=O)N(C)C)=C3C2=CNC3=C1 VUEGYUOUAAVYAS-JGGQBBKZSA-N 0.000 description 2
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 2
- WGMHMVLZFAJNOT-UHFFFAOYSA-N 1-ethoxyethylideneazanium;chloride Chemical compound [Cl-].CCOC(C)=[NH2+] WGMHMVLZFAJNOT-UHFFFAOYSA-N 0.000 description 2
- LXGCTJHPIPIZGL-BDCODIICSA-N 2,2,2-trichloroethyl (2r)-2-(2-methylpropyl)-6-phenyl-3-[phenylmethoxy(phenylmethoxycarbonyl)carbamoyl]hexanoate Chemical compound C=1C=CC=CC=1CON(C(=O)OCC=1C=CC=CC=1)C(=O)C([C@@H](CC(C)C)C(=O)OCC(Cl)(Cl)Cl)CCCC1=CC=CC=C1 LXGCTJHPIPIZGL-BDCODIICSA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 2
- VVCMGAUPZIKYTH-VGHSCWAPSA-N 2-acetyloxybenzoic acid;[(2s,3r)-4-(dimethylamino)-3-methyl-1,2-diphenylbutan-2-yl] propanoate;1,3,7-trimethylpurine-2,6-dione Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O.CN1C(=O)N(C)C(=O)C2=C1N=CN2C.C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 VVCMGAUPZIKYTH-VGHSCWAPSA-N 0.000 description 2
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 2
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 2
- RUROFEVDCUGKHD-UHFFFAOYSA-N 3-bromoprop-1-enylbenzene Chemical compound BrCC=CC1=CC=CC=C1 RUROFEVDCUGKHD-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 108091007505 ADAM17 Proteins 0.000 description 2
- 102000043279 ADAM17 Human genes 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 101100515517 Arabidopsis thaliana XI-I gene Proteins 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- PGWRITFIZNPILR-UHFFFAOYSA-N CCCCC(CCCC1=CC=CC=C1)C(=O)N(C(=O)OCC2=CC=CC=C2)OCC3=CC=CC=C3 Chemical compound CCCCC(CCCC1=CC=CC=C1)C(=O)N(C(=O)OCC2=CC=CC=C2)OCC3=CC=CC=C3 PGWRITFIZNPILR-UHFFFAOYSA-N 0.000 description 2
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 2
- 206010006895 Cachexia Diseases 0.000 description 2
- 101100460385 Caenorhabditis elegans nhx-2 gene Proteins 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 229940126639 Compound 33 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 2
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 2
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FOQDEZQXAFRQMH-UHFFFAOYSA-N N'-ethylethanimidamide hydrochloride Chemical compound Cl.CCN=C(C)N FOQDEZQXAFRQMH-UHFFFAOYSA-N 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 101710108790 Stromelysin-1 Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 2
- WREOTYWODABZMH-DTZQCDIJSA-N [[(2r,3s,4r,5r)-3,4-dihydroxy-5-[2-oxo-4-(2-phenylethoxyamino)pyrimidin-1-yl]oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N(C=C\1)C(=O)NC/1=N\OCCC1=CC=CC=C1 WREOTYWODABZMH-DTZQCDIJSA-N 0.000 description 2
- PQLVXDKIJBQVDF-UHFFFAOYSA-N acetic acid;hydrate Chemical compound O.CC(O)=O PQLVXDKIJBQVDF-UHFFFAOYSA-N 0.000 description 2
- 229960003767 alanine Drugs 0.000 description 2
- 125000005237 alkyleneamino group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000003368 amide group Chemical group 0.000 description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 125000004104 aryloxy group Chemical group 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- SNCZNSNPXMPCGN-UHFFFAOYSA-N butanediamide Chemical compound NC(=O)CCC(N)=O SNCZNSNPXMPCGN-UHFFFAOYSA-N 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940126543 compound 14 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- 229940125833 compound 23 Drugs 0.000 description 2
- 229940127204 compound 29 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 229940126540 compound 41 Drugs 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000006114 decarboxylation reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ORMNPSYMZOGSSV-UHFFFAOYSA-N dinitrooxymercury Chemical compound [Hg+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ORMNPSYMZOGSSV-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- XGZRAKBCYZIBKP-UHFFFAOYSA-L disodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[Na+] XGZRAKBCYZIBKP-UHFFFAOYSA-L 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000006862 enzymatic digestion Effects 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- JMIAPORGEDIDLT-UHFFFAOYSA-N ethyl ethanimidate Chemical compound CCOC(C)=N JMIAPORGEDIDLT-UHFFFAOYSA-N 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 150000002460 imidazoles Chemical class 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- RXOMLHJELPQREP-UHFFFAOYSA-N n'-propan-2-ylbutanediamide Chemical compound CC(C)NC(=O)CCC(N)=O RXOMLHJELPQREP-UHFFFAOYSA-N 0.000 description 2
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 125000005499 phosphonyl group Chemical group 0.000 description 2
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical compound OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 235000010199 sorbic acid Nutrition 0.000 description 2
- 239000004334 sorbic acid Substances 0.000 description 2
- 229940075582 sorbic acid Drugs 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 108091007196 stromelysin Proteins 0.000 description 2
- 239000001384 succinic acid Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 150000003512 tertiary amines Chemical class 0.000 description 2
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 239000000052 vinegar Substances 0.000 description 2
- 235000021419 vinegar Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- CYNQKJPFHUKKSF-MRVPVSSYSA-N (2R)-4-methyl-2-propylpentanoic acid Chemical compound C(C(C)C)[C@H](C(=O)O)CCC CYNQKJPFHUKKSF-MRVPVSSYSA-N 0.000 description 1
- KSLFSWRZBRBZRT-QNSVNVJESA-N (2r)-2-[3-[4-(methanesulfonamidomethyl)phenyl]-1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)C(C(=O)OC(C)(C)C)CC1=CC=C(CNS(C)(=O)=O)C=C1 KSLFSWRZBRBZRT-QNSVNVJESA-N 0.000 description 1
- NNFDHJQLIFECSR-RXMQYKEDSA-N (2r)-2-bromo-4-methylpentanoic acid Chemical compound CC(C)C[C@@H](Br)C(O)=O NNFDHJQLIFECSR-RXMQYKEDSA-N 0.000 description 1
- XTCNGAJYWUIFFB-SSDOTTSWSA-N (2r)-2-ethyl-4-methylpentanoic acid Chemical compound CC[C@@H](C(O)=O)CC(C)C XTCNGAJYWUIFFB-SSDOTTSWSA-N 0.000 description 1
- QYHOPSMZMBFQGN-ZYMOGRSISA-N (2r)-3-[(2-methylpropan-2-yl)oxycarbonyl]-2-(2-methylpropyl)-5-phenoxypentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)C(C(=O)OC(C)(C)C)CCOC1=CC=CC=C1 QYHOPSMZMBFQGN-ZYMOGRSISA-N 0.000 description 1
- TWNDMKARFABYKR-WUBHUQEYSA-N (2r)-3-[(2-methylpropan-2-yl)oxycarbonyl]-2-(2-methylpropyl)-6-(4-phenylmethoxyphenyl)hexanoic acid Chemical compound C1=CC(CCCC([C@@H](CC(C)C)C(O)=O)C(=O)OC(C)(C)C)=CC=C1OCC1=CC=CC=C1 TWNDMKARFABYKR-WUBHUQEYSA-N 0.000 description 1
- HKFPNFGORVGIPL-WUBHUQEYSA-N (2r)-3-[(2-methylpropan-2-yl)oxycarbonyl]-2-(2-methylpropyl)-6-[4-(phenylmethoxycarbonylamino)phenyl]hexanoic acid Chemical compound C1=CC(CCCC([C@@H](CC(C)C)C(O)=O)C(=O)OC(C)(C)C)=CC=C1NC(=O)OCC1=CC=CC=C1 HKFPNFGORVGIPL-WUBHUQEYSA-N 0.000 description 1
- JGYWDKDECUBHOA-OEMAIJDKSA-N (2r)-3-[(2-methylpropan-2-yl)oxycarbonyl]-2-(2-methylpropyl)-6-morpholin-4-ylhexanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)C(C(=O)OC(C)(C)C)CCCN1CCOCC1 JGYWDKDECUBHOA-OEMAIJDKSA-N 0.000 description 1
- AXKVPAGAFXYPHP-ZYMOGRSISA-N (2r)-3-[(2-methylpropan-2-yl)oxycarbonyl]-2-(2-methylpropyl)-6-piperidin-1-ylhexanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)C(C(=O)OC(C)(C)C)CCCN1CCCCC1 AXKVPAGAFXYPHP-ZYMOGRSISA-N 0.000 description 1
- QWRHBTUUPHJCDG-WUBHUQEYSA-N (2r)-3-[(2-methylpropan-2-yl)oxycarbonyl]-2-(naphthalen-2-ylmethyl)-6-phenylhexanoic acid Chemical compound CC(C)(C)OC(=O)C([C@@H](CC=1C=C2C=CC=CC2=CC=1)C(O)=O)CCCC1=CC=CC=C1 QWRHBTUUPHJCDG-WUBHUQEYSA-N 0.000 description 1
- SBFKFYAPPGVMTR-ZYMOGRSISA-N (2r)-3-[(2-methylpropan-2-yl)oxycarbonyl]-6-phenyl-2-propan-2-ylhexanoic acid Chemical compound CC(C)(C)OC(=O)C([C@@H](C(C)C)C(O)=O)CCCC1=CC=CC=C1 SBFKFYAPPGVMTR-ZYMOGRSISA-N 0.000 description 1
- VZSMNJBNPMXSLM-QVDQXJPCSA-N (2r)-4-methyl-2-[1-[(2-methylpropan-2-yl)oxy]-1-oxopropan-2-yl]pentanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)C(C)C(=O)OC(C)(C)C VZSMNJBNPMXSLM-QVDQXJPCSA-N 0.000 description 1
- IVTUFYQJCLPNJU-YSSOQSIOSA-N (2r)-5-butoxy-3-[(2-methylpropan-2-yl)oxycarbonyl]-2-(2-methylpropyl)pentanoic acid Chemical compound CCCCOCCC([C@@H](CC(C)C)C(O)=O)C(=O)OC(C)(C)C IVTUFYQJCLPNJU-YSSOQSIOSA-N 0.000 description 1
- VQAHXMBSIODQFM-QRWMCTBCSA-N (2r)-6-cyclohexyl-3-[(2-methylpropan-2-yl)oxycarbonyl]-2-(2-methylpropyl)hexanoic acid Chemical compound CC(C)C[C@@H](C(O)=O)C(C(=O)OC(C)(C)C)CCCC1CCCCC1 VQAHXMBSIODQFM-QRWMCTBCSA-N 0.000 description 1
- PZVHMLQLXAUQGY-LURJTMIESA-N (2s)-2,6-diamino-n-methylhexanamide Chemical compound CNC(=O)[C@@H](N)CCCCN PZVHMLQLXAUQGY-LURJTMIESA-N 0.000 description 1
- RZENOPCSYJWNKU-VIFPVBQESA-N (2s)-2-(aminomethylamino)-3-phenylpropanoic acid Chemical compound NCN[C@H](C(O)=O)CC1=CC=CC=C1 RZENOPCSYJWNKU-VIFPVBQESA-N 0.000 description 1
- WXUPNROOSXELJT-VIFPVBQESA-N (2s)-6-amino-2-(butoxycarbonylamino)hexanoic acid Chemical compound CCCCOC(=O)N[C@H](C(O)=O)CCCCN WXUPNROOSXELJT-VIFPVBQESA-N 0.000 description 1
- MHAFOZCRAWLAKI-OEMAIJDKSA-N (3r)-5-methyl-2-(3-phenylpropyl)-3-(2,2,2-trichloroethoxycarbonyl)hexanoic acid Chemical compound ClC(Cl)(Cl)COC(=O)[C@H](CC(C)C)C(C(O)=O)CCCC1=CC=CC=C1 MHAFOZCRAWLAKI-OEMAIJDKSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- DEVSOMFAQLZNKR-RJRFIUFISA-N (z)-3-[3-[3,5-bis(trifluoromethyl)phenyl]-1,2,4-triazol-1-yl]-n'-pyrazin-2-ylprop-2-enehydrazide Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(C2=NN(\C=C/C(=O)NNC=3N=CC=NC=3)C=N2)=C1 DEVSOMFAQLZNKR-RJRFIUFISA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- DJMOXMNDXFFONV-UHFFFAOYSA-N 1,3-dimethyl-7-[2-(n-methylanilino)ethyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCN(C)C1=CC=CC=C1 DJMOXMNDXFFONV-UHFFFAOYSA-N 0.000 description 1
- ZNYIPTYJBRGSSL-UHFFFAOYSA-N 1,5,5-trimethylimidazolidine-2,4-dione Chemical compound CN1C(=O)NC(=O)C1(C)C ZNYIPTYJBRGSSL-UHFFFAOYSA-N 0.000 description 1
- QHVKNGCASMQYGJ-UHFFFAOYSA-N 1-(2-iodoethoxy)butane Chemical compound CCCCOCCI QHVKNGCASMQYGJ-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- GYSCBCSGKXNZRH-UHFFFAOYSA-N 1-benzothiophene-2-carboxamide Chemical compound C1=CC=C2SC(C(=O)N)=CC2=C1 GYSCBCSGKXNZRH-UHFFFAOYSA-N 0.000 description 1
- RMSGQZDGSZOJMU-UHFFFAOYSA-N 1-butyl-2-phenylbenzene Chemical group CCCCC1=CC=CC=C1C1=CC=CC=C1 RMSGQZDGSZOJMU-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- FPZWZCWUIYYYBU-UHFFFAOYSA-N 2-(2-ethoxyethoxy)ethyl acetate Chemical group CCOCCOCCOC(C)=O FPZWZCWUIYYYBU-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- BPKJNEIOHOEWLO-RXMQYKEDSA-N 2-amino-n,3,3-trimethylbutanamide Chemical compound CNC(=O)[C@@H](N)C(C)(C)C BPKJNEIOHOEWLO-RXMQYKEDSA-N 0.000 description 1
- BKMMTJMQCTUHRP-UHFFFAOYSA-N 2-aminopropan-1-ol Chemical compound CC(N)CO BKMMTJMQCTUHRP-UHFFFAOYSA-N 0.000 description 1
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
- UVEVMKODWDQIAN-UHFFFAOYSA-N 2h-chromene-3-carboxamide Chemical compound C1=CC=C2OCC(C(=O)N)=CC2=C1 UVEVMKODWDQIAN-UHFFFAOYSA-N 0.000 description 1
- VJXIFKZHWWSQBD-UHFFFAOYSA-N 3-butylpyrrolidine-2,5-dione Chemical compound CCCCC1CC(=O)NC1=O VJXIFKZHWWSQBD-UHFFFAOYSA-N 0.000 description 1
- HVSJHYFLAANPJS-UHFFFAOYSA-N 3-iodo-2-methylprop-1-ene Chemical compound CC(=C)CI HVSJHYFLAANPJS-UHFFFAOYSA-N 0.000 description 1
- QMYGFTJCQFEDST-UHFFFAOYSA-N 3-methoxybutyl acetate Chemical group COC(C)CCOC(C)=O QMYGFTJCQFEDST-UHFFFAOYSA-N 0.000 description 1
- LVFPDQUAUOUBPO-UHFFFAOYSA-N 3-methyl-3-(phenylmethoxycarbonylamino)butanoic acid Chemical compound OC(=O)CC(C)(C)NC(=O)OCC1=CC=CC=C1 LVFPDQUAUOUBPO-UHFFFAOYSA-N 0.000 description 1
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
- UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 101100460384 Arabidopsis thaliana NHX2 gene Proteins 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 125000006519 CCH3 Chemical group 0.000 description 1
- 101150071146 COX2 gene Proteins 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- 101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Natural products CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 239000004258 Ethoxyquin Substances 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 241000255777 Lepidoptera Species 0.000 description 1
- 206010024305 Leukaemia monocytic Diseases 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 241000080590 Niso Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- GPRAXDNHOJFZQH-UHFFFAOYSA-N OC=1C(=C(C2=C(NN=N2)C1)O)O Chemical compound OC=1C(=C(C2=C(NN=N2)C1)O)O GPRAXDNHOJFZQH-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 101150000187 PTGS2 gene Proteins 0.000 description 1
- 241001602688 Pama Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 101150085390 RPM1 gene Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000256011 Sphingidae Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010021119 Trichosanthin Proteins 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- SAHIZENKTPRYSN-UHFFFAOYSA-N [2-[3-(phenoxymethyl)phenoxy]-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound O(C1=CC=CC=C1)CC=1C=C(OC2=NC(=CC(=C2)CN)C(F)(F)F)C=CC=1 SAHIZENKTPRYSN-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DTVLINYCUONXFY-UHFFFAOYSA-N acetic acid;methanamine Chemical compound NC.CC(O)=O.CC(O)=O DTVLINYCUONXFY-UHFFFAOYSA-N 0.000 description 1
- GCPWJFKTWGFEHH-UHFFFAOYSA-N acetoacetamide Chemical compound CC(=O)CC(N)=O GCPWJFKTWGFEHH-UHFFFAOYSA-N 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical class CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000005277 alkyl imino group Chemical group 0.000 description 1
- 125000005037 alkyl phenyl group Chemical group 0.000 description 1
- 125000004422 alkyl sulphonamide group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- CBTVGIZVANVGBH-UHFFFAOYSA-N aminomethyl propanol Chemical compound CC(C)(N)CO CBTVGIZVANVGBH-UHFFFAOYSA-N 0.000 description 1
- 229940101006 anhydrous sodium sulfite Drugs 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229940000489 arsenate Drugs 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000001691 aryl alkyl amino group Chemical group 0.000 description 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 239000005667 attractant Substances 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- IQTGXJIELWZFIM-UHFFFAOYSA-N benzyl n-(5-iodopentyl)carbamate Chemical compound ICCCCCNC(=O)OCC1=CC=CC=C1 IQTGXJIELWZFIM-UHFFFAOYSA-N 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- XUHFBOUSHUEAQZ-UHFFFAOYSA-N bromobenzyl cyanide Chemical compound N#CC(Br)C1=CC=CC=C1 XUHFBOUSHUEAQZ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- AKXRWRQEECPABP-UHFFFAOYSA-N butyl n-hydroxycarbamate Chemical compound CCCCOC(=O)NO AKXRWRQEECPABP-UHFFFAOYSA-N 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000006315 carbonylation Effects 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- OQNGCCWBHLEQFN-UHFFFAOYSA-N chloroform;hexane Chemical compound ClC(Cl)Cl.CCCCCC OQNGCCWBHLEQFN-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 201000008230 cutaneous porphyria Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- ARUKYTASOALXFG-UHFFFAOYSA-N cycloheptylcycloheptane Chemical group C1CCCCCC1C1CCCCCC1 ARUKYTASOALXFG-UHFFFAOYSA-N 0.000 description 1
- UKJLNMAFNRKWGR-UHFFFAOYSA-N cyclohexatrienamine Chemical group NC1=CC=C=C[CH]1 UKJLNMAFNRKWGR-UHFFFAOYSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
- CZHYKKAKFWLGJO-UHFFFAOYSA-N dimethyl phosphite Chemical compound COP([O-])OC CZHYKKAKFWLGJO-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- OOYIOIOOWUGAHD-UHFFFAOYSA-L disodium;2',4',5',7'-tetrabromo-4,5,6,7-tetrachloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3',6'-diolate Chemical compound [Na+].[Na+].O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC(Br)=C([O-])C(Br)=C1OC1=C(Br)C([O-])=C(Br)C=C21 OOYIOIOOWUGAHD-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- ZUNGGJHBMLMRFJ-UHFFFAOYSA-O ethoxy-hydroxy-oxophosphanium Chemical compound CCO[P+](O)=O ZUNGGJHBMLMRFJ-UHFFFAOYSA-O 0.000 description 1
- DECIPOUIJURFOJ-UHFFFAOYSA-N ethoxyquin Chemical compound N1C(C)(C)C=C(C)C2=CC(OCC)=CC=C21 DECIPOUIJURFOJ-UHFFFAOYSA-N 0.000 description 1
- 235000019285 ethoxyquin Nutrition 0.000 description 1
- 229940093500 ethoxyquin Drugs 0.000 description 1
- MVEAAGBEUOMFRX-UHFFFAOYSA-N ethyl acetate;hydrochloride Chemical compound Cl.CCOC(C)=O MVEAAGBEUOMFRX-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- QFWPJPIVLCBXFJ-UHFFFAOYSA-N glymidine Chemical compound N1=CC(OCCOC)=CN=C1NS(=O)(=O)C1=CC=CC=C1 QFWPJPIVLCBXFJ-UHFFFAOYSA-N 0.000 description 1
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 238000007327 hydrogenolysis reaction Methods 0.000 description 1
- 238000007031 hydroxymethylation reaction Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- RGFNRWTWDWVHDD-UHFFFAOYSA-N isobutyl butyrate Chemical compound CCCC(=O)OCC(C)C RGFNRWTWDWVHDD-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- LZWQNOHZMQIFBX-UHFFFAOYSA-N lithium;2-methylpropan-2-olate Chemical compound [Li+].CC(C)(C)[O-] LZWQNOHZMQIFBX-UHFFFAOYSA-N 0.000 description 1
- MUERZYSPGYLGBT-UHFFFAOYSA-N lithium;molecular hydrogen Chemical compound [Li].[H][H] MUERZYSPGYLGBT-UHFFFAOYSA-N 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- BRMYZIKAHFEUFJ-UHFFFAOYSA-L mercury diacetate Chemical compound CC(=O)O[Hg]OC(C)=O BRMYZIKAHFEUFJ-UHFFFAOYSA-L 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940126170 metalloproteinase inhibitor Drugs 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- WDTHVZZVBMSAQL-UHFFFAOYSA-N methanesulfonamide;toluene Chemical group CS(N)(=O)=O.CC1=CC=CC=C1 WDTHVZZVBMSAQL-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- ZBELDPMWYXDLNY-UHFFFAOYSA-N methyl 9-(4-bromo-2-fluoroanilino)-[1,3]thiazolo[5,4-f]quinazoline-2-carboximidate Chemical compound C12=C3SC(C(=N)OC)=NC3=CC=C2N=CN=C1NC1=CC=C(Br)C=C1F ZBELDPMWYXDLNY-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- BCIONRHKNKQXEY-UHFFFAOYSA-N methylazanium;pentanoate Chemical compound [NH3+]C.CCCCC([O-])=O BCIONRHKNKQXEY-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 201000006894 monocytic leukemia Diseases 0.000 description 1
- GUAQVFRUPZBRJQ-UHFFFAOYSA-N n-(3-aminopropyl)-2-methylprop-2-enamide Chemical compound CC(=C)C(=O)NCCCN GUAQVFRUPZBRJQ-UHFFFAOYSA-N 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000006503 p-nitrobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1[N+]([O-])=O)C([H])([H])* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- XLCISDOVNFLSGO-VONOSFMSSA-N phorbol-12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(O)C1(C)C XLCISDOVNFLSGO-VONOSFMSSA-N 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- UHPXMYLONAGUPC-WKLLBTDKSA-N pivmecillinam hydrochloride Chemical compound [H+].[Cl-].N([C@H]1[C@@H]2N(C1=O)[C@H](C(S2)(C)C)C(=O)OCOC(=O)C(C)(C)C)=CN1CCCCCC1 UHPXMYLONAGUPC-WKLLBTDKSA-N 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 108010029690 procollagenase Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- OGHBATFHNDZKSO-UHFFFAOYSA-N propan-2-olate Chemical compound CC(C)[O-] OGHBATFHNDZKSO-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 108010052605 prostromelysin Proteins 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 230000006103 sulfonylation Effects 0.000 description 1
- 238000005694 sulfonylation reaction Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- LMYRWZFENFIFIT-UHFFFAOYSA-N toluene-4-sulfonamide Chemical compound CC1=CC=C(S(N)(=O)=O)C=C1 LMYRWZFENFIFIT-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- OACSUWPJZKGHHK-UHFFFAOYSA-N tribenzyl phosphate Chemical compound C=1C=CC=CC=1COP(OCC=1C=CC=CC=1)(=O)OCC1=CC=CC=C1 OACSUWPJZKGHHK-UHFFFAOYSA-N 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
- C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
- C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4025—Esters of poly(thio)phosphonic acids
- C07F9/405—Esters of poly(thio)phosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a novel compound inhibiting meta-oral proteinase, an intermediate for producing the same, and a method for producing them. More preferably, the present invention inhibits vertebrate-derived matrix metaoral proteinases (MMPs) and Z or 3 ⁇ 4 ⁇ E factor-a (TNF-a) converting enzyme, The present invention relates to excellent novel compounds, intermediates for producing the same, and methods for producing them.
- MMPs vertebrate-derived matrix metaoral proteinases
- TNF-a 3 ⁇ 4 ⁇ E factor-a
- MMPs matrix meta-oral proteinases
- TNF- is produced as a 26K membrane-bound precursor and is considered to be released extracellularly, causing diseases such as sepsis and rheumatoid arthritis.
- the enzyme that causes the release of TNF- ⁇ is a meta-oral proteinase, and it has been strongly reported that its activity is controlled by sP and a harmful agent [A.J.H. Gearing et al., Journal of Leukocyte Biology, 57, 774 (1995), KM Mohler et al., Nature, 370, 218 (1994), GM NcGeehan et al., Nature, 370, 558 (1994)].
- the present inventors have focused on hydroxamic acid attractants having high inhibitory activity against MMPs, and have conducted intensive studies in order to enhance their utility. As a result, it has a high meta-oral proteinase inhibitory activity and, in addition to the compounds described above, dramatically improves the drug's bioavailability and biological activity, such as oral absorption, in comparison with the above compounds.
- the present inventors have found a novel hydroxamic acid derivative and have made the present invention.
- R 1 is hydrogen, an optionally substituted aralkyl group, a silinole group having three substituents, a tetrahydroviranyl group, an optionally substituted aralkyloxycarbonyl group, Represents an optionally substituted alkyloxycarbonyl group, an optionally substituted alkyl group, or a hydroxyl-protecting group,
- R 2 is hydrogen, an optionally substituted aralkyloxycarbonyl group, an optionally substituted alkyloxycarbonyl group, a 9-fluorenylmethyloxycarbonyl group, or a protecting group for an amino group Represents
- R 3 represents hydrogen, a hydroxyl group, an optionally substituted alkyl group, or an optionally substituted aralkyl group,
- IT represents an optionally substituted alkyl group or an optionally substituted aralkyl group
- R 5 and may be the same or different and are hydrogen, an optionally substituted alkyl group, an optionally substituted cycloalkynole group, an optionally substituted heterocyclic Or a protecting group for an amino group, or R 5 and R 6 together with the nitrogen atom to which they are attached, are substituted or may represent a heterocyclic group;
- R 7 represents hydrogen, a hydroxyl group, an optionally substituted alkyl group, or an optionally substituted aralkyl group,
- R 8 represents hydrogen, a hydroxyl group, an optionally substituted alkyl group, or an optionally substituted aralkyl group,
- R 9 represents hydrogen, hydroxyl, amino, or -XY;
- X represents an optionally substituted (d-CJ alkylene group or an optionally substituted phenylene group
- Y represents -A-B group or -B group
- A represents an optionally substituted (Ci_C 6 ) alkylene group, oxygen, sulfur, imino group, or an optionally substituted (C, -C 6 ) alkyleneimino group,
- B is a 7k element, an amino group, an amidino group, an acylimidyl group, an optionally substituted imidazolyl group, an optionally protected bisphosphonomethyl group, or an optionally protected bisphosphonohydroxymethyl group Represents
- R 3 is a (d-C 9 ) alkyl group, a (C 3 -C 7 ) cycloalkyl-substituted (-CJ lower alkynole group, a hydroxyl group, an amino-substituted (CC 6 ) alkyl group, a phenyl (C “) fil alkyl group, guanido-substituted phenyl (C, -) lower alkyl group, Amino substituted phenyl (-) lower alkyl, carboxy-substituted phenyl (- C 4) a lower alkyl group, Karubamo I-substituted phenyl (CC-lower alkyl group, hydroxy-substituted Phenyl (C) lower alkyl group, guanide-substituted () lower alkyl-substituted phenyl (C-C) lower alkyl group, optionally protected amino-substitute
- R 4 represents a (C 3 -C 9 ) alkyl group, a hydroxy-substituted (C 3 -C 8 ) alkyl group, or a substituted or unsubstituted (C, -C 4 ) quaternary alkyl group
- R 5 is, (-) ⁇ alkyl, (C 3 -C 7) cycloalkyl group, mono- or di (d -C 4) lower alkylamino-substituted (d -cj lower alkyl group, a carboxy-substituted (C ⁇ loweralkyl group, a hydroxy-substituted alkyl group (C 6 to C), bis phosphono hydro Kishimechiru substituted (C alkyl group, tetramethylene base Nji bis phosphono hydroxy methylation substituted (d -CM) alkyl group or a nitrogen-containing heterocycle, A formula group,
- R 6 is hydrogen
- R 8 is hydrogen or a (-) lower alkyl group
- R 9 is hydrogen, hydroxyl, amino, or -XY,
- X is (d-C alkylene group or phenylene group
- Y is -A-B group or -B group
- B represents hydrogen, amino group amidino group, () lower acylimidoyl group, optionally substituted benzimidoinole group, bisphosphonomethyl group, tetra (C) lower alkylbisphosphonomethyl group, tri () fif and alkyl bisphosphonomethyl, bisphosphonohydroxymethyl, tetrabenzylbisphosphonohydroxymethyl, or (C) -C 4 ) lower alkyl-substituted imidazole 3-yl;
- A is (d-C lower alkylene group, imino group, or (-) class alkyleneimino group, the compound according to the above [1];
- R 3 is a hydroxyl group, a methyl group, an isobutyl group, an aminopropyl group, a phenylpropionyl group, a guanidophenylpropyl group, an aminophenylpropyl group, a hydroxyphenylpropyl group, a carboxyphenylpropyl group, a carbamoylphenyl group; Nylpropyl group, aminomethylphenylpropyl group, guanidomethylphenylpropyl group, hydroxymethylphenylpropyl group, aminomethylbenzyl group, toluenesulfonamide methylbenzene group, methanesulfonamide methylbenzene group, Isobutyliminomethylbenzinole group, phthalimidmethylbenzinole group, phenyloxinetinole group, amaminopentyl group, acetimidoyliminopentyl group, isobutyliminopent
- R 4 is a naphthylmethyl group, a phenylpropyl group, an isobutynole group, a tert-butyl group, an isopropyl group, or a hydroxyoctyl group;
- R 6 is hydrogen
- R 8 is hydrogen or a methyl group
- R 9 is hydrogen, hydroxyl, amino, or -X ⁇
- X is a methylene group, an ethylene group, a trimethylene group, a tetramethylene group, a pentamethylene group, a hexamethylene group, or a phenylene group;
- ⁇ is - ⁇ - ⁇ or ⁇
- A is an imino group, a methyleneimino group or a methylene group
- the compound represented by the general formula (I) according to the above [1] or a pharmaceutically acceptable salt thereof is a pharmaceutically acceptable salt with a compound selected from the group consisting of solvates.
- the meta-mouth proteinase according to the above (5) which is one of members belonging to mW ⁇ -a (TNF-a) converting enzyme and is a TNF- ⁇ converting enzyme inhibitor.
- the Esuteno position of the compound represented in converted into Ami de-bond-containing site optionally R M, R 1 2, R 1 3 and 4, respectively varying the R 3, RR 5 and 9 is a functional group of the object conversion either, or a compound represented by the general formula (IV), optionally R u, R '2, R ' 3 and 4 R 3 is a functional group of purposes, R ⁇ R 5 and respectively converted to IT And then converting the esteno position to an amide bond-containing site, wherein the compound represented by the general formula (I) according to (1) above, or a pharmaceutically acceptable salt or Method for producing compound selected from the group consisting of solvates
- R ′ to R 9 have the same meaning as those described in the above [1],
- R 10 represents an alkyl group which may be substituted, an aralkyl group which may be substituted, or a carboxyl group-protecting group;
- R " is the same as defined above for R 3 , or a protected hydroxyl group, a protected guanidyl-substituted phenyl (C 4 ) dialkyl group, a protected amino-substituted phenyl (CC class alkyl group, Nitro-substituted phenyl (-C 4 ) lower alkyl, protected amino-substituted (-C alkyl, nitro-substituted (C 6 C) -alkyl, protected power Rupoxy-substituted phenyl (d-C 4 ) lower alkyl Group, protected hydroxy-substituted phenyl (d-lower alkyl, protected guanide-substituted (d-) lower alkyl-substituted phenyl (C to ⁇ ) lower alkyl, protected amino-substituted () phenyl substituted with an alkyl group (to C) lower alkyl group, protected hydroxy
- R 12 is as defined above for R 4 , or represents a protected hydroxy-substituted ( ⁇ -C 8 ) alkyl group;
- R 13 has the same meaning as R 5 above, or a protected carboxy-substituted (d-C 4 ) lower alkyl group, a protected hydroxy-substituted (C,-) lower alkyl group, a protected bis Phosphonohydroxymethyl-substituted (d-C n) alkyl groups, or protected
- R is as defined above for R 9 , protected amino, protected hydroxyl, -X-E or -X-AE (where X and A are as defined above, Is a nitro group, a cyano group, an amino group, a carboxyl group, a hydroxy (-C) alkyl group, a protected amino group, a protected guanide group, a protected amidino group, a protected acylimidoyl group, Represents a protected benzimidyl group, a protected bisphosphonomethyl group, a protected bisphosphonohydroxymethyl group, or a protected (C, -CM) alkyl-substituted imidazole-3-yl group ]
- R 10 represents a (d-C 6 ) alkyl group, a benzyl group, a substituted benzyl group, a phenacene group, or a 2,2,2-trichloroethyl group;
- R 12 has the same meaning as R 4 or a protected hydroxyoctyl group
- R 13 has the same meaning as R 5 , or a protected 2-carboxyethyl group, a protected 2-hydroxyethynole group, a protected 2-hydroxy-1, trimethylethyl group, a protected Represents a 2-hydroxy-methylethyl group or a protected 6,6-bisphosphono-6-hydroxyhexynole group,
- R 14 has the same meaning as R 9 , a protected amino group, a protected hydroxyl group, a —XF group or a —X-A-F group (where X and A are as defined above, F stands for nitro, cyano, amino, carboxyl, hydroxymethyl, protected amino, protected guanide, protected amidino, protected acetimidoyl, protected propionimid
- F stands for nitro, cyano, amino, carboxyl, hydroxymethyl, protected amino, protected guanide, protected amidino, protected acetimidoyl, protected propionimid
- R ′ R 9 has the same meaning as described in the above (1)
- R ′, RR 6 to R 8 have the same meaning as described in the above (1),
- R 6 to R 8 have the same meanings as described in [1], R, (l to R M is the
- R 6 to R 8 have the same meanings as those described in the above [1]
- R 13 and IT have the same meanings as those described in the above [9].
- the present invention provides a pharmaceutically acceptable salt or solvate thereof.
- the present invention provides a pharmaceutically acceptable salt or solvate thereof.
- R 3 represents hydrogen, a hydroxyl group, an unsubstituted or substituted (- ⁇ alkyl group, an unsubstituted or substituted aryl (d-C 6 ) alkyl group,
- R 6 are the same or different and represent hydrogen, an unsubstituted or substituted (C Cu) alkyl group, a (C 3 -C 6 ) cycloalkyl group or a heterocyclyl group,
- R 7 represents hydrogen, a hydroxyl group, an unsubstituted or substituted (d-C 6 ) alkyl group, an unsubstituted or substituted aryl (C 6 ) alkyl group,
- R 8 represents hydrogen, a hydroxyl group, an unsubstituted or substituted (-C B ) alkyl group, an unsubstituted or substituted aryl (d-C 6 ) alkyl group,
- R 9 represents hydrogen, a hydroxyl group, an amino group, or an XY group
- X represents a (C, -C 6 ) alkylene group or a phenylene group
- Y represents a - ⁇ - ⁇ group or a-(group (where (represents a (d-CJ alkylene group, imino group or (C, -C 6 ) alkyleneimino group
- B represents hydrogen, amino Group, an amidino group, an acylimidyl group, an unsubstituted or substituted imidazolyl group, an optionally protected bisphosphonomethyl group or an optionally protected bisphosphonohydroxymethyl group.
- R ′ and R 2 are hydrogen
- R 3 is a hydroxyl group, a methyl group, an isobutyl group, an aminopropyl group, a 3-phenylpropyl group, a P-guanidophenylpropyl group, a P-aminophenylpropyl group, a p-hydroxyphenylpropyl group, a -hydroxypropyl group Pill group, m-hydroxypropyl group, p-aminomethylphenylpropyl group, p-guanidomethylphenylpropyl group, p-hydroxymethylphenylpropynole group, p-aminomethylbenzyl group, m -Aminomethylbenzinole group, 0-Aminomethylbenzyl group, p-Toluenesulfonamidomethylbenzyl group, p-Methanesulfonamidomethylbenzyl group, p-Isobutyliminomethylbenzyl group, P-phthalimid Me
- R 5 is a methyl group, a cyclopropyl group, a 2- (N, N-dimethylamino) ethyl group, a 2-potoxyloxyethyl group, a 2-hydroxyethynole group, a 2-hydroxy-1, trimethylethynole group, a 2-hydroxy-1 -Methylethyl, 6,6-bisphosphono-6-hydroxyhexyl, tetrabenzyl 6,6-bisphosphono-6-hydroxyhexyl, piberdinole or morpholinyl; R 6 is hydrogen,
- R 8 is hydrogen or a methyl group
- R 9 is hydrogen, hydroxyl, amino, or -XY,
- X is a methylene group, an ethylene group, a trimethylene group, a tetramethylene group, a pentamethylene group, a hexamethylene group or a phenylene group;
- A is an imino group, a methyleneimino group, or a methylene group
- MMPs Matrix meta-oral proteinases containing a compound represented by the general formula (I) and Z or km i-a
- TNF- Using a meta-oral proteinase inhibitor characterized by inhibiting the activity of the enzyme
- a process for producing a compound of the general formula (I)
- R ⁇ R 5 and 1 R 9 is a functional group of interest To convert the ester moiety to an amide compound, or
- R ′ to R 9 are as defined above, R '° represents a carboxyl-protecting group ((C, -C 6 ) alkyl, benzyl, substituted benzylinole, phenacinole, or 2,2,2-trichloroethyl);
- R 12 is the same as R 4 or represents a protected hydroxyoctyl group
- R '3 were ,, or protected as defined force and R 5 2 Karubokishechiru groups, protected 2 - hydroxy E butyl group, protected 2-hydroxy-1, Bok Jimechiruechiru groups were protected Represents a 2-hydroxy-methylethyl group or a protected 6,6-bisphosphono-6-hydroquinhexyl group;
- R is the same as R fl or represents -XG or -XA-G (where X and A have the same meanings as above, and G is nitro, cyano, amino, carboxyl, hydroxymethyl Group, protected amino group, protected guanido group, protected amidino group, protected acetimidoyl group, protected propionimidoyl group, protected benzimidoyl group, protected bisphosphono A methyl group, representing a protected bisphosphonohydroxymethyl group); and
- R '1, R' 2, R 1 3 and R 1 4 R 3 is a functional group of purposes, R ⁇ R 5 and R 9 Niso Re formula to Toku ⁇ the conversion, respectively by Nozomu Tokoro (
- the compound represented by (I) or a stereoisomer thereof, and a chemically acceptable salt thereof are produced by a method for producing a solvate.
- the carbons of (1) and (4) have an R configuration or an S configuration; Carbon has S configuration, and (3) carbon has S configuration.
- the present invention provides
- R ′ to R 3 , R ⁇ R 6 and Y have the same meanings as described in the above (1), wherein R 3 is preferably hydrogen, a 7k acid group, or substituted May be Ariru (d-C 6) alkyl group, Y is - A- where a B group - A- particularly preferable ones among the group, (-) alkyleneimino group or Imino group,, -B group Among them, particularly preferred are hydrogen, acetateimidinole group, propionimidoyl group, benzimidinole group, amidino group, or bisphosphonomethyl group.
- acetate imido group particularly preferred are an acetate imido group, a propion imido group, a benzimidoyl group, or an amidino group, and Ra is hydrogen or substituted in the substituent X described in the above [1].
- the compound represented by the general formula (1-1) according to the above [22], or a pharmaceutically acceptable salt thereof, is a compound selected from the group consisting of solvates as an active ingredient.
- meta-oral proteinase is one of members belonging to ® »E factor-a (TNF-a) converting enzyme, and is a TNF-a converting enzyme inhibitor.
- the invention provides a method comprising:
- R ′ to R 3 , R 5 , R 6 and Y have the same meanings as described in the above (1), and the substituent of the (unsubstituted or substituted alkylene) group is [1] has the same meaning as the alkylene group which may be substituted in the substituent X described in [1]], or a pharmaceutically acceptable salt or solvate thereof. ;
- a pharmaceutical and / or veterinary composition comprising an acceptable carrier
- the compound represented by the general formula (1-2) according to the above (28) or a pharmaceutically acceptable salt thereof is a compound selected from the group consisting of solvates as an active ingredient.
- the inhibitor of the above-mentioned [30] which is one of members belonging to the class of meta-oral proteinases or 'meta-oral proteinases' and is a matrix meta-oral proteinase inhibitor;
- the invention provides a method comprising:
- R 6 , R 7 and R 8 have the same meanings as described in the above (1), and R 13 is hydrogen, an alkyl group which may be substituted, Substituted with an alkyl group, an optionally substituted heterocyclic group, or a protecting group for an amino group, or with R 6 together with the nitrogen atom to which they are attached. Represents a good heterocyclic group,
- R M represents a hydroxyl group, an amino group, the -X- G group or -XAG group represented (where the X, have the same meaning as above SL [1], wherein, A is optionally substituted (d-CJ represents an alkylene group, an oxygen, an imino group, or an optionally substituted (-C 6 ) alkylene amino group, and G represents an optionally protected bisphosphonomethynole group or a bisphospho group. Represents a nonhydroxymethyl group)]
- the compound represented by the general formula (III) described in the above [34], or a pharmaceutically acceptable salt thereof, is a compound that is pharmaceutically acceptable with a compound selected from the group consisting of solvates.
- the compound represented by the general formula (III) described in the above [34], or a pharmaceutically acceptable salt thereof ⁇ , contains as an active ingredient a compound selected from the group consisting of solvates.
- An bone breaking agent characterized by the following;
- the term “and / or” means that both (1) a merged connection and (2) a selective connection exist, such as “prevention and / or treatment” In the sense that it includes both (1) prevention and treatment and (2) prevention or treatment. In other cases, the term “and / or” is similarly used to encompass both (1) merged connection relationships and (2) selective connection relationships.
- the "optionally substituted alkyl group” may be optionally substituted with one or more substituents (the substituents may be selected from those described below). Or a branched chain, and the number of carbon atoms is preferably 1 to 20, more preferably 1 to 12, and particularly preferably 1 to 9.
- the carbon number of the alkylene moiety is preferably 1 to 8, more preferably from 1 to 4, wherein the alkylene moiety may be ⁇ or a branched chain; and a typical aralkyl group is an optionally substituted phenyl-substituted ( C-CJ lower alkyl groups (or also “phenyl (also referred to as -M-grade alkylene groups)” include, for example, benzyl, 2- or 4-nitrobenzyl, optionally substituted such as 4-methoxybenzyl and the like.
- Ben may be Optionally substituted phenyl, optionally substituted phenylpropyl (also referred to as “phenyltrimethylene”), naphthylpropyl (also referred to as “naphthyltrimethylene”), and the like.
- the “optionally substituted alkyl moiety” in the “optionally substituted alkyloxycarbonyl group” is the same as R 1 , R 3 , R ⁇ R 5 , R 6 , R 7 , R 8 or those selected from the same as the “optionally substituted alkyl group” in R ′ °;
- Examples of the "alkyloxycarbonyl group” include (C, -Ce) alkyloxycarbonyl group such as a tert-butyloxycarbonyl group.
- the ⁇ optionally substituted aralkyloxy I ⁇ minute '' in the ⁇ optionally substituted aralkyloxycarbonyl group '' is
- the "optionally substituted aralkylkine carbonyl group” is, for example, benzyloxycarbonyl, 2- or 4-nitrobenzyloxycarbonyl And optionally substituted benzyloxycarbonyl, such as 4-methoxybenzyloxycarbonyl and 4-methoxybenzyloxycarbonyl, and optionally substituted phenyloxycarbonyl.
- a silyl group having three substituents is an alkyl group which may be substituted and z or a substituent which may be substituted. Those having an aryl group and z or an aralkyl group which may be substituted are strongly mentioned, and the ⁇ aralkyl group which may be substituted '' for these substituents is selected from the same as those described above. It is what is done. Further, the “optionally substituted alkyl group” of the substituted moiety is also an “optionally substituted alkyl group” in the above R 1 , R 3 , R ⁇ RR 6 , R ⁇ R 8 or R ′ °. Are selected from the same ones.
- the “optionally substituted aryl group” of the substituted group is the “aryl group of the optionally substituted aralkyl group” of RR 3 , R 7 , R 8 or R 1 Q. And the like, and examples thereof include a phenyl group and a naphthyl group.
- Representative examples of the “silyl group having three substituents” include, for example, a trialkylsilinole group such as a trimethylsilinole group, a tert-butyldimethylsilyl group, and a tert-butyldiphenylsilyl group. And the like.
- “optionally substituted cycloalkyl group” means one or more substituents (substituents as described below) May be arbitrarily substituted by a force that is of the Kagyu formula, or :! ⁇ It may be a condensed form of a plurality of rings such as the formula, and the number of carbon atoms is preferably 3 to 10, more preferably 3 to 7, particularly preferably 3 to 6, for example. , Cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, [2.2.1] bicycloheptyl and the like.
- the “optionally substituted heterocyclic group” may be saturated or unsaturated, and may be the same or different, It may contain an elementary atom, an oxygen atom, a sulfur atom, etc., and may be of the art form, or a condensed form of a plurality of rings such as a bicyclic ring.
- the substituent can be selected from those described below). It may be replaced.
- Examples of the "optionally substituted heterocyclic group” include, for example, those having a 5-, 6- or 7-membered ring, typically, imidazole, pyrazonole, imidazoline, imidazolidin, pyridine, Pyrimidine, benzimidazole, quinazoline, pteridine, purine, 1,3-dazepine, aziridine, azetidine, pyrrol, pyrrolidine, tetrahydropyridine, piperidine, azepine, indole, quinoline, isoquinoline, morpholine, pyridine And so on.
- R 5 and R 6 are taken together with the nitrogen atom to which they are attached to form an “optionally substituted heterocyclic group”, the group is a monocyclic ring containing a nitrogen atom. It may be of the formula or a fused form of a plurality of rings of the formula or the like; saturated or unsaturated may be, for example, aziridine, azetidine, pyrrole, Pyrrolidine, pyridine, tetrahydropyridine, piperidine, azepine, indole, quinoline, isoquinoline, morpholine, piperazine and the like.
- the general formula (I) and "protecting group" of the "protected hydroxyl group” or R 1 1 and 1 in 4 "hydroxyl protecting group” in R 'in (IV) are, in the field of organic synthesis Those known to those skilled in the art, for example, those that have been used in the fields of peptide synthesis, penicillin synthesis, cephalosporin synthesis, sugar synthesis, etc .;
- the "hydroxyl coercive Mamorumoto" and the "protecting group” it shall removable by treatment with water, those removable by solution hydrogenation component, for example, removed by a Lewis acid 3 ⁇ 4 such A1C1 3 And acetic acid, thiourea, acid or weak base, benzyl, 2,2,2-trichloromouth ethoxyquincarbonyl, aryloxy Examples include carbonyl, 2-methoxyethoxymethyl, formyl, acetyl, chloroacetyl, dichloroacetyl, and trityl.
- the group may be a group capable of forming a hydroxyl group biologically, that is, under biological conditions (for example, oxidation or reduction by an in vivo enzyme, or an in vivo reaction such as hydrolysis, or the like) or Any group that can be changed to that may be used, and the group may be shifted.
- the “protecting group for hydroxyl group” and the “protecting group” include the above “silyl group having three substituents”, “optionally substituted aralkyl group”, tetrahydrobiranyl group, “substituted And an optionally substituted alkyloxycarbonyl group and an optionally substituted aralkyloxycarbonyl group.
- the “protecting group for an amino group” is known to those skilled in the art of organic synthesis. , For example, selected from protecting groups that have been used in fields such as peptide synthesis, penicillin synthesis, cephalosporin synthesis, and sugar synthesis.
- protecting groups that have been used in fields such as peptide synthesis, penicillin synthesis, cephalosporin synthesis, and sugar synthesis.
- Examples of the “protecting group for an amino group” include those which can be removed by hydrogenolysis, those which can be removed with fluoride, those which can be removed with acid, and benzyloxycarbonyl, p-nitro.
- Benzyloxycarbonyl, trityl, tert-butoxycarbonyl, for example, formyl, chloroacetinol, dichloroacetyl, etc., may be optionally substituted with a nitrogen atom (CC 6 ).
- alkoxycarbonyl such as 2,2,2-trichloroethoxycarbonyl, aryloxycarbonyl, and 2-methoxyethoxymethyl.
- a group may be a biologically active group, such as a live cow (for example, an in vivo reaction such as acid reduction or hydrolysis by an in vivo enzyme) or a chemically free amino group. Or any group capable of forming a protonated form thereof or a group capable of being converted thereto.
- Examples of the "protecting group for an amino group” include the above-mentioned “optionally substituted alkyloxycarbonyl group”, “optionally substituted aralkyloxycarbonyl group”, and 9-fluorenylmethyloxycarbonyl Examples include those selected from groups.
- Examples of the substituent in the “optionally substituted cycloalkyl group” and the “optionally substituted heterocyclic group” include the above-mentioned alkyl group, the above-mentioned aryl group, hydroxyl group, and the like.
- amino groups for example, amino, for example, N-lower () alkylamino such as methylamino, ethylamino, isopropylamino, N-arylamino such as phenylamino, for example, Aralkylamino, such as lysylmethylamino and benzylamino, for example, morpholino, piperidino, piperazino, alicyclic amino, such as N-phenylbiperazino, guanidino, etc., amidino group, acylimidinole group (eg, acetimidinoline group)
- acylisimidoyl group includes, as described above, for example, an acetoimidoinole group, a propionimidoyl group, etc. ( ⁇ -((: derived from 2 -alkanoic acid, a benzimidoinole group, etc. C 7 _Cn) those derived from aromatic carboxylic acids.
- the term “protecting group for carboxyl group” is known to those skilled in the art of organic synthesis, and has been used in fields such as peptide synthesis, penicillin synthesis, cephalosporin synthesis, and sugar synthesis. Selected from protecting groups.
- the “protecting group for carboxyl group” can be selected from the same groups as those described above for “protecting group for hydroxyl group”, and can be used by hydrogenation, treatment with acid or weak base, or the like. And the like.
- Each of the protecting groups in the -3-yl group is selected from the corresponding ones of the above-mentioned "hydroxyl protecting group", “amino group protecting group” and “carboxyl group protecting group”. Can be used.
- Some of the compounds of the formula (I) of the present invention exist as two tautomers.
- the compounds of the present invention have an asymmetric carbon in the compound of the formula (I) and exist as a stereoisomer with respect to the carbon.
- the present invention includes the mixture of the isomers as well as the respective standing forms.
- the compounds of the present invention may be enantiomers, racemates, and diastereomers.
- the compound of the present invention may be a solvate or an acid addition salt thereof, a compound having a carboxyl group in the substituent and / or a compound having a hydroxyl group, and Z or an amino group which may be substituted.
- any prodrug derived therefrom includes those which can be converted into a compound of the formula (I) in vivo by metabolism, for example, by hydrolysis, oxidation, reduction, transesterification, or the like. This includes, for example, esters, ethers, amides, alcohols, amine derivatives.
- R IU , R ′′ and R 12 have the same meanings as described above, and R 1 , R 16 and 7 may be the same or different, respectively, a protecting group for a carboxy group, For example, an optionally substituted (CC 6 ) alkyl group, benzyl group, substituted benzyl group, phenacyl group or 2,2,2-trichloroethyl group, and D represents a substitutable group such as halogen )
- the route for synthesizing the compound of the general formula (II) which is useful as a production intermediate, is suitable for all cases except for R "which is strongly hydrogen and hydroxyl groups. It is.
- the compound of the general formula (X) is obtained by reacting a compound of the general formula (VI 11) obtained by anilating a ⁇ -halogenocarboxylic acid ester (IX), which is a logen, with a malonic diester of the general formula (VI 1).
- halogen include fluorine, chlorine, bromine and iodine, with bromine being preferred.
- Examples of the base used for anionization of the malonic acid diester (VII) include those used in usual reactions, such as alkali metal hydrides (for example, sodium hydrogen hydride), lithium disopropyla Alcohols such as amide (LDA), lithium bis (trimethylsilyl) amide, alkali metal alcoholates (eg, sodium methoxide, sodium ethoxide, sodium propoxide, potassium tert-butoxide, potassium ethoxide, etc.) And preferably hydrogen hydride or lithium-tert-butoxide.
- alkali metal hydrides for example, sodium hydrogen hydride
- lithium disopropyla Alcohols such as amide (LDA), lithium bis (trimethylsilyl) amide
- alkali metal alcoholates eg, sodium methoxide, sodium ethoxide, sodium propoxide, potassium tert-butoxide, potassium ethoxide, etc.
- alkali metal alcoholates eg, sodium methoxide, sodium eth
- the reaction solvent can use an inert organic solvent, for example, saturated hydrocarbons (eg, n-hexane, etc.), ethers (eg, tetrahydrofuran (THF), etc.), aromatic hydrocarbons (eg, , Benzene, toluene, etc.), amides (for example, dimethylformamide (DMF), dimethylacetamide (DMAc), etc.), and halogenated hydrocarbons (for example, dichloromethane, chloroform, etc.)
- the force that can be used is preferably DMF.
- the reaction S3 ⁇ 4 is usually at 78 to 50 ° C, preferably at 0 to 20 ° C.
- the reaction time varies depending on the starting materials, solvent, reaction temperature, etc., and a reaction time of 30 minutes to 4 hours is sufficient, and usually 1 hour to 2 hours.
- an inert organic solvent can be used as a reaction solvent.
- saturated hydrocarbons for example, n Hexane, etc.
- ethers eg, THF, etc.
- aromatic hydrocarbons eg, benzene, toluene, etc.
- amides eg, DMF, DMAc, etc.
- halogenated hydrocarbons eg, Dichloromethane, chloroform, etc.
- the reaction is usually at -10 to 50 ° C, preferably at -5 to 0 ° C.
- the reaction time varies depending on the starting material, solvent, reaction and the like used, and is usually 2 to 24 hours, preferably 10 to 20 hours.
- the compound of the general formula (XI I) is obtained by converting the compound of the general formula (X) into an anion compound (XI), and halogenated (Ci-C 6 ) alkyl (preferably iodide (-C c ) such as methyl iodide).
- Alkyl substituted (-C 6 ) alkyl halide (preferably benzyloxycarbonylamino-3-odopropane, 1-benzyloxycarbonylamino-5-iodopentane, 1-tetrahydrovilla) Nyloxy-8-iodooctane, triethoxyethoxy-2-iodoethane, 1-n-butyloxy-2-iodoethane, 1-iso-butynoleoxy-2-iodoethane, triphenoxy-2-odoethane
- Examples of the base used in the synthesis of the compound of formula (XI) include those generally used in this type of reaction, such as LDA, lithium bis (trimethylsilinole) amide, and alkali metal.
- alkali metal eg, sodium hydride
- alkali metal alcoholates eg, sodium methoxide, sodium methoxide, sodium propoxide, potassium tert-butoxide, potassium ethoxide, etc.
- alcohols are used, and preferably sodium hydride is used.
- An inert organic solvent can be used as the reaction solvent.
- saturated hydrocarbons eg, n-hexane etc.
- ethers eg, THF, etc.
- aromatic hydrocarbons eg, Benzes toluene, etc.
- Amides eg, DMF, DMAc, etc.
- halogenated hydrocarbons eg, dichloromethane, chloroform, etc.
- the reaction is usually at -10 to 50 ° C, preferably at 10 to 30 ° C.
- the reaction time varies depending on the starting material, solvent, reaction temperature and the like used, but is usually 30 minutes to 4 hours, preferably 1 hour to 2 hours.
- an inert organic solvent can be used as the reaction solvent, and for example, saturated hydrocarbons (eg, n-hexane and the like), ethers (eg, THF) ), Powers of aromatic hydrogens (eg, benzene, toluene), amides (eg, DMF, DMAc, etc.), halogenated hydrocarbons (eg, dichloromethane, chloroform, etc.) Preferably, it is DMF.
- the reaction temperature is usually -10 to 100 ° C, preferably -5 to 70 ° C.
- the reaction time varies depending on the starting material, solvent, reaction, etc., and is usually 2 hours to 48 hours, preferably 10 hours to 20 hours.
- hydrogenation is carried out to obtain a compound of the general formula (XI I) by using a palladium horn butterfly such as palladium carbon or a horn butterfly such as platinum as a hydrogenated hornworm medium. Palladium on carbon.
- a palladium horn butterfly such as palladium carbon or a horn butterfly such as platinum as a hydrogenated hornworm medium. Palladium on carbon.
- an inert organic solvent that does not become horn butterfly venom can be used.
- alcohols methanol, ethanol, etc.
- amides eg, DMF, DMAc, etc.
- acetic acid Alternatively, water can be used, and a mixture thereof is also used, and methanol or ethanol is preferable.
- the reaction is usually carried out at 0 to 50 ° C, preferably 10 to 30 ° C.
- the reaction time is usually 1 hour to 24 hours, preferably 1 hour to 10 hours, depending on the starting material, solvent, reaction & g used and the like.
- the compound of the general formula (XI II) is produced by deesterification of the general formula (II).
- R ′ °, R ′ 5 , R ′ 6 are as defined above, and give a compound of the general formula (XI II)
- Butyl group, R 1 5 and R 1 6 Gabe Njiru groups are preferred - R 1 0 is tert in.
- R 15 and 6 can be deesterified by hydrogenation of the benzyl group.
- a catalyst such as palladium carbon and platinum can be used, and palladium carbon is preferable.
- a reaction solvent an inert organic solvent which does not become a corner butterfly poison can be used.
- alcohols methanol, ethanol, etc.
- amides eg, DMF, DMAc, etc.
- acetic acid or water And mixtures thereof are also used, preferably methanol or ethanol.
- Reaction i3 ⁇ 43 ⁇ 4 is usually 0 to 50 ° C, preferably 10 to 30 ° C.
- the reaction time varies depending on the starting materials, the solvent, the reaction, and the like, but is usually 1 hour to 24 hours, preferably 1 hour to 10 hours.
- a route for synthesizing a compound of the general formula (II) useful as a production intermediate from a compound of the general formula (XIV) as a starting material is suitable for a compound in which R 3 is hydrogen or a hydroxyl group.
- the compound represented by the general formula (XV) can be obtained by converting the succinic acid derivative represented by the general formula (XIV) into (a) ⁇ , ⁇ '-dicyclohexylcarpoimide (DCC), 1-ethyl-3- (3-dimethyla).
- a compound of the formula (XIV) with a thionyl chloride-alcohol complex ⁇ (c) there is no particular limitation on the alcohol used, for example, methanol, ethanol, n-propyl alcohol, iso-propyl alcohol Tert-butyl alcohol, phenol, benzyl alcohol, phenacyl alcohol, 2,2,2-trichloroethanol, and the like (preferably, methanol, ethanol, is0-propyl alcohol, tert-butyl alcohol). And more preferably is 0-propyl alcohol.) Also used as a reaction solvent.
- the alcohol used for example, methanol, ethanol, n-propyl alcohol, iso-propyl alcohol Tert-butyl alcohol, phenol, benzyl alcohol, phenacyl alcohol, 2,2,2-trichloroethanol, and the like (preferably, methanol, ethanol, is0-propyl alcohol, tert-butyl alcohol). And more preferably is 0-propyl alcohol.) Also used as
- the reaction temperature is usually ⁇ 30 to 10 ° C., preferably ⁇ 10 to 0 ° C.
- the reaction time varies depending on the starting material, solvent, reaction and the like used, and is usually 5 to 24 hours, preferably 10 to 15 hours.
- the compound of the general formula (XVI) can be produced by anionizing the succinic diester of the general formula (XV), reacting with methallyl monozide, and then hydrogenating.
- Examples of the base used for anionization of the succinic diester (XV) include those used in ordinary reactions, such as alkali metal hydrides (eg, sodium hydrogen hydride), LDA, lithium bis Use of alcohols such as (trimethylsilinole) amides, alkali metal alcoholates (eg, sodium methoxide, sodium ethoxide, sodium propoxide, potassium-tert-butoxide, potassium ethoxide, etc.) Force, preferably LDA.
- alkali metal hydrides eg, sodium hydrogen hydride
- LDA lithium bis Use of alcohols such as (trimethylsilinole) amides, alkali metal alcoholates (eg, sodium methoxide, sodium ethoxide, sodium propoxide, potassium-tert-butoxide, potassium ethoxide, etc.) Force, preferably LDA.
- the reaction solvent may be an inert organic solvent such as saturated hydrocarbons (eg, n-hexane, etc.), ethers (eg, THF, etc.), aromatic hydrocarbons (eg, benzene, toluene, etc.), and amines. (Eg, DMF, DMAc, etc.), halogenated hydrocarbons (eg, dichloromethane, chloroform, etc.), etc., preferably THF.
- the reaction temperature is usually -78 to 0 ° C, preferably -70 to -10 ° C.
- the reaction time varies depending on the starting material, solvent, reaction temperature, etc. used, and is 0 minute to 24 hours, and usually 4 hours to 12 hours.
- an inert organic solvent can be used as a reaction solvent, for example, saturated hydrocarbons (for example, n-hexane and the like), ethers (for example, THF, etc.), aromatic hydrocarbons (eg, benzene, toluene, etc.), amides (eg, DMF, DMAc, etc.), halogenated hydrocarbons (eg, dichloromethane, chloroform, etc.), etc. are used.
- saturated hydrocarbons for example, n-hexane and the like
- ethers for example, THF, etc.
- aromatic hydrocarbons eg, benzene, toluene, etc.
- amides eg, DMF, DMAc, etc.
- halogenated hydrocarbons eg, dichloromethane, chloroform, etc.
- the reaction temperature is usually -78 to 0 ° C, preferably -70 to -10 ° C.
- the reaction time is usually 2 hours to 48 hours, preferably 10 hours to 20 hours, which varies depending on the starting material, the solvent, the reaction i, etc., to be used.
- a corner butterfly such as palladium carbon or platinum as a hydrogenation catalyst, and preferably palladium carbon.
- reaction solvent an inert organic solvent that does not cause keratotoxicity can be used.
- alcohols methanol, ethanol, etc.
- amides eg, DMF, DMAc, etc.
- acetic acid or water are used.
- it is methanol.
- the reaction temperature is It is usually 0 to 50 ° C, preferably 10 to 30 ° C.
- the reaction time is usually 1 hour to 24 hours, preferably 1 hour to 6 hours, depending on the starting material, solvent, reaction and the like used.
- the compound of the general formula (XVI I) can be produced by deesterifying the compound of the general formula (XVI). For example, when 17 is an iso-propyl group, it can be deesterified by alkaline hydrolysis.
- the base used for the hydrolysis is not particularly limited as long as it is used as a base in the usual reaction. Examples thereof include sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, and hydrogen carbonate. Sodium, lithium hydrogen hydride, sodium hydride and the like, and preferably sodium hydroxide sodium, lithium hydroxide and the like.
- the reaction solvent is not particularly limited as long as it does not hinder the progress of the reaction and can dissolve the raw materials, but amides (eg, DMF, DMAc, etc.), alcohols, ethers (eg, Jethyl ether) , Tetrahydrofuran, dioxane, etc.), water, ketones (eg, acetone) and the like, and preferably alcohols, water, dioxane, acetone or a mixed solvent thereof.
- the reaction is usually at -20 to 150 ° C, preferably at -10 to 100 ° C.
- the reaction time is usually from 5 minutes to 36 hours, preferably from 10 minutes to 24 hours.
- Compounds of general formula ( ⁇ ) useful as synthetic intermediates can be prepared by (a) decarboxylation of compounds of general formula (XI 11) or (b) " ⁇ from dicarboxylic acids of formula (XVI I) xvm) can be produced by reacting with alcohols via water.
- the reaction & g is usually from 70 to 150 ° C, preferably from 100 to 120 ° C.
- the reaction time varies depending on the starting material, solvent, reaction, etc., and is usually 1 hour to 5 hours, preferably 2 hours to 3 hours.
- the reaction for producing the production intermediate (II) from the dicarboxylic acid of the general formula (XVI I) via the hydrate of the general formula (XVI ⁇ ) is described, for example, in [J. Org. Cea, 47, 4928 (1982)].
- the alcohol to be reacted with the acid anhydride (XVI II) is not particularly limited.
- methanol, ethanol, ⁇ -propyl alcohol, iso-propyl alcohol, tert-butyl alcohol, phenol, benzyl alcohol, phenacyl alcohol Nole, 2,2,2-trichloroethanol, etc. preferably methanol, ethanol, benzyl alcohol, 2,2,2-trichloroethanol
- R 6 , R 7 , R 8 , R 13 and 4 are as defined above, and R 18 is, for example, a tert-butyloxycarbonyl (Boc) group, a benzyloxy O) a protecting group for an amino group such as a bonyl (Z) group or a substituted benzyloxycarbonyl group; o)
- R M is a -XE group or an X-A-E group
- Compounds that are powerful are powerful (a) protected bisphosphonomethyl groups, (b) protected bisphosphonohydroxymethyl groups, and (c) substituted imidazolylmethyl groups are those that have E-amino groups, carboxy groups.
- a hydroxymethyl group can be produced from the conjugate of the general formula (XXI I).
- E of the strongly protected bisphosphonomethyl group ⁇ , protected 4'-aminophenylalanine is converted to a formate such as ethyl ethyl formate and a phosphite such as diethyl phosphite. [See Phosphorous and Sul fur 11, 311 (1981)].
- (C) B is a substituted imizolylmethyl group
- ⁇ is a protected immobilized 4'-hydroxymethylphenylalanine, which is treated with methyl sulfonyl or p-toluenesulfonyl, followed by imidazole binding.
- the reaction can be produced [see J. Med. Chem, 31, 2193 (1988)].
- the reaction is usually carried out at 100 to 180 ° C, preferably 140 to 160 ° C.
- the reaction time varies depending on the starting material used, the reaction temperature, etc., and is generally 1 hour to 8 hours, preferably 1 hour to 6 hours.
- the reaction to convert the protected 4 '_carboxylphenylalanine to an acid halide can be carried out, for example, by reacting a thionylc or oxalylc mouth with DMF. It is obtained by reacting with a salt prepared using the above method.
- a reaction solvent an inert solvent can be strongly used.
- amides eg, DMF, etc.
- ethers eg, dimethyl ether, etc.
- halogenated hydrocarbons eg, dichloromethane, chloroform, etc.
- Holm etc.
- the reaction ⁇ is usually from -20 to 100 ° C, preferably from -5 to 80 ° C.
- the reaction time is usually from 5 minutes to 24 hours, preferably from 10 minutes to 8 hours.
- trialkylphos in the presence of one equivalent of a proton donor (preferably alcohol, acetic acid, etc.), which is converted to a protected bisphosphonohydroxymethyl group. React with sulfurite.
- a proton donor preferably alcohol, acetic acid, etc.
- an inert solvent can be used as the reaction solvent.
- amides eg, DMF etc.
- ethers eg, Jethyl ether etc.
- halogenated hydrocarbons eg, dichloromethane, chloroform, etc.
- the intermediate sulfonylated compound is obtained by adding protected 4'-hydroxymethylphenylalanine and a sulfonating agent in the presence of a base.
- Sulfonylation! ⁇ Is strongly exemplified by alkylsulfonyl halides such as methanesulfonyl chloride, p-toluenesulfonyl chloride, arylsulfonyl halide, and the like.
- the base is preferably an alkylamine such as trialkylamine, or a nitrogen-containing heterocyclic compound such as pyridine; ⁇ is preferably triethylamine.
- an inert solvent can be used as a reaction solvent.
- amides eg, DMF, DMAc, etc.
- aromatic hydrocarbons eg, benzene, etc.
- ethers eg, Jethyl ether, etc.
- Halogenated hydrocarbons eg, dichloromethane, chloroform, etc.
- the reaction temperature is usually -20 to 50 ° C, preferably -5 to 20 ° C.
- the reaction time is usually 10 minutes to 4 hours, preferably 30 minutes to 2 hours.
- a compound of the general formula (XXII), which is a strongly substituted imidazolylmethyl group can be obtained.
- anionization include those used in ordinary reactions, such as alkali metal hydrides (eg, sodium hydride), LDA, lithium bis (trimethylsilyl) amide, and alkali metal alcoholates. (For example, sodium methoxide, sodium ethoxide, sodium propoxide, potassium tert-butoxide, potassium ethoxide, etc.). It is.
- the compound of the general formula (XX) is produced by introducing a protecting group such as a Boc group, a Z group, or a substituted benzyloxycarbonyl group to the amino group of the compound of the general formula (XIX) by a conventional method. I can do it.
- a protecting group such as a Boc group, a Z group, or a substituted benzyloxycarbonyl group
- i ⁇ of the Z group can be obtained by reacting a benzyl benzoate in the presence of a commonly used base (e.g., sodium carbonate, potassium carbonate, sodium hydrogen carbonate, sodium hydroxide, hydroxylated lime). Can be introduced.
- a commonly used base e.g., sodium carbonate, potassium carbonate, sodium hydrogen carbonate, sodium hydroxide, hydroxylated lime.
- reaction solvent examples include ethers (eg, dioxane, etc.), ketones (eg, acetone, etc.), water, and mixed solvents thereof.
- the reaction is usually at -20 to 30 ° C, preferably at -5 to 5 ° C.
- the reaction time is generally 2 hours to 24 hours, preferably 6 hours to 15 hours.
- R 13 is preferably a hydrogen having the same meaning as described above, and is preferably an alkyl group (more preferably a methyl group), a (C 3- ) alkyl group (or preferably a cyclopropyl group), optionally substituted (- C 4) alkyl groups (more preferably 2-N, N-Jimechiruechiru group, protected 2-carbonitrile Kishechiru groups, protected 2-hydroxy-E A tyl group, a protected 2-hydroxy-1,1-dimethylethyl group, a protected 2-hydroxy-1-methylethyl group, a protected 6,6-bisphosphono-6-hydroquin hexinole group) or a heterocyclinole Group (even better
- the preferred condensing agents are DCC, BDC
- the reaction temperature is usually -20 to 50 ° C, preferably -15 to 30 ° C.
- the reaction time is generally 1 hour to 24 hours, preferably 2 hours to 15 hours.
- Compounds of general formula (m) useful as intermediates are prepared by removing the amino protecting group of a compound of formula ⁇ ).
- a method for removing the protecting group a conventional method widely known to those skilled in the art is applied to each method according to the method. For example, 3 ⁇ 4 ⁇ in which the protecting group is a z group is a hydrogenation power ⁇ a preferable removal method.
- As the hydrogenation furnace it is preferable to use palladium carbon, platinum or the like.
- the reaction solvent is not particularly limited as long as it is an inert organic solvent that does not cause venom, but alcohols (methanol, ethanol, etc.), amides (eg, DMF, DMAc, etc.), acetic acid or water are used. And preferably methanol.
- the reaction ⁇ is usually at 0 to 50 ° C, preferably at 10 to 30 ° C.
- the reaction time varies depending on the starting material, solvent, reaction temperature and the like used, but is usually 1 hour to 24 hours, preferably 1 hour to 6 hours.
- the compound of the general formula (XXI11) is produced by deesterifying the compound of the general formula (XII).
- R '. , R 15 and R 16 are the same as defined above.
- R 10 and R 'Is preferably a benzyl group.
- R 10 and R ′ 5 can be deesterified by hydrogenation of a benzyl group.
- An angle ffi such as palladium carbon or platinum can be used as the hydrogenated angle butterfly, but palladium carbon is preferred.
- the reaction solvent an inert organic solvent that does not cause corner horn venom can be used, and examples thereof include alcohols (methanol, ethanol, etc.), THF, DMF, DMAc, acetic acid, and water, and a mixture thereof. Strong, preferably THF.
- Reaction i3 ⁇ 43 ⁇ 4 is usually 0 to 50 ° C., preferably 10 to 50 ° C. ⁇ 30 ° C.
- the reaction time varies depending on the starting material, solvent, reaction temperature and the like used, and is generally 1 hour to 24 hours, preferably 1 hour to 6 hours.
- the compound of the general formula (XXIV) can be obtained by converting succinic acid derivative ( ⁇ ) to N, N'-dicyclohexylcarbodiimide (DCC), trethyl-3- (3-dimethylaminopropyl) -carbodiimide hydrochloride It can be produced by reacting with an alcohol in the presence of a condensing agent such as (EDO HC1) and a base such as N-dimethylaminopyridine.
- a condensing agent such as (EDO HC1)
- a base such as N-dimethylaminopyridine.
- the alcohol used is not particularly limited, and includes, for example, methanol, ethanol, n-propyl alcohol, iso-propyl alcohol, tert-butyl alcohol, phenol, benzyl alcohol, phenacyl alcohol, 2,2,2-trichloroethanol, and the like. (Preferably, 2,2,2-trichloromouth ethanol).
- an inert organic solvent can be used as the reaction solvent.
- saturated hydrocarbons eg, n-hexane, etc.
- ethers eg, THF, etc.
- aromatic hydrocarbons eg, benzene, Toluene, etc.
- amides eg, DMF, DMAc, etc.
- halogenated hydrocarbons eg, dichloromethane, chloroform, etc.
- the reaction temperature is usually -30 to 30 ° C, preferably -10 to 20 ° C.
- the reaction time varies depending on the starting material, solvent, reaction temperature and the like used, but is usually 1 hour to 24 hours, preferably 3 hours to 15 hours.
- the compound of the general formula (XXV) can be obtained by (a) decarboxylation of the compound of the general formula (XXI ⁇ ) or (b) partial deesterification of the compound of the general formula (XXIV). Can be
- reaction temperature is usually 70 to 150 ° C, preferably 100 to 120 ° C.
- reaction time varies depending on the starting material, solvent, reaction temperature and the like to be used, but is usually 1 hour to 5 hours, preferably 2 hours to 3 hours.
- a corner butterfly such as palladium carbon or platinum can be used as the hydrogenated corner butterfly, but palladium carbon is preferred.
- a reaction solvent an inert organic solvent that does not cause horn butterfly venom can be used.
- alcohols methanol, ethanol, etc.
- ethers eg, THF, etc.
- amides eg, DMF, DMAc, etc.
- acetic acid or water is used, preferably THF.
- the reaction is usually performed at 0 to 50 ° C, preferably 10 to 30 ° C.
- the reaction time is usually 1 hour to 24 hours, preferably 1 hour to 6 hours, depending on the starting material, solvent, reaction key and the like used.
- TFA trifluoroacetic acid
- organic solvent ethyl acetate, dioxane, etc.
- TFA is used as the solvent.
- the reaction is usually at -10 to 50 ° C, preferably at 0 to 30 ° C.
- the reaction time varies depending on the diester (XXIV) used, the acid, the reaction temperature and the like, but is usually 30 minutes to 24 hours, preferably 1 hour to 15 hours.
- ⁇ compound of formula (XXVI I) are varying half ester of (XXV) into an acid halide ⁇ , protected protecting group of the force ⁇ RR 2 which can be prepared by reacting a hydroxy ⁇ Min (XXVI) and R R ′ 6 is preferably a 2,2,2-trichloroethyl group for the purpose of selectively removing 16 protecting groups.
- the reaction for converting the compound to an acid or a ride can be obtained by reacting thionyl chloride or oxalyl chloride with a salt-forming dimethyl chloroform-formimidium prepared using DMF.
- a reaction solvent an inert solvent can be used.
- aromatic hydrocarbons eg, benzene, toluene, etc.
- amides eg, DMF, DMAc, etc.
- ethers eg, getyl) Ethers
- halogenated hydrocarbons eg, dichloromethane, chloroform, etc.
- the reaction is usually at ⁇ 20 to 100 ° C., preferably at ⁇ 5 to 80 ° C.
- the reaction time is usually from 5 minutes to 24 hours, preferably from 10 minutes to 8 hours.
- the resulting intermediate is an inert solvent that can be used by reacting with protected hydroxyamine (XXVI) in the presence of a base.
- a base for example, aromatic hydrocarbons (eg, benzene, toluene, etc.), amides (eg, DMF, DAc, etc.), ethers (eg, getyl ether, etc.), halogenated hydrocarbons (eg, dichloromethane, Etc.), but dichloromethane is preferred.
- tertiary amines such as trialkylamine, pyridine and the like can be mentioned, and triethylamine is preferable.
- the reaction is usually at -20 to 50 ° C, preferably at -5 to 30 ° C.
- the reaction time is usually from 5 minutes to 24 hours, preferably from 10 minutes to 5 hours.
- the compound of the general formula (V) can be obtained by deesterifying the compound of the general formula (XXVI I). For example, in the case of R 16 and 2,2,2-trichloroethyl group, it can be removed by using acetic acid as a reaction solvent and treating with zinc.
- the reaction is usually carried out at 0 to 50 ° C, preferably 5 to 40 ° C.
- the reaction time is usually 30 minutes to 15 hours, preferably 1 hour to 5 hours.
- each group of R ′ to R 14 is as defined above.
- the compound of the general formula (IV) is produced by reacting the intermediate (II) with the intermediate (in) by a conventional coupling technique.
- R ′ is a powerful compound having the same meaning as described above, and protection of the carboxyl group.
- Groups for example, an alkyl group which may be substituted, an aralkyl group which may be substituted, and the like, preferably a tert-butyl group, a benzyl group, a substituted benzyl group, a phenacinole group, a 2,2,2- A trichloromethyl group, and particularly preferably a tert-butyl group or a benzyl group.
- condensing agent for this reaction examples include, for example, DCC, EDC ⁇ HC1, EEDQ, HOB :, H0NB-derived :, HOSu-derived
- the reaction solvent is not particularly limited as long as it does not hinder the progress of the reaction and dissolves the raw materials.
- examples thereof include amides (eg, DMF, DMAc, etc.), esters (eg, ethyl acetate, etc.), ethers (Eg, getyl ether, dioxane, etc.) and halogenated hydrocarbons (eg, dichloromethane, chloroform, etc.).
- the reaction i ⁇ is usually ⁇ 20 to 50 ° C., preferably ⁇ to 30 ° C.
- the reaction time is generally 1 hour to 24 hours, preferably 2 hours to 15 hours.
- the compound of the general formula (XXVI11) is produced by subjecting the compound of the formula (IV) to deesterification and, if desired, converting R 2 into a desired functional group.
- the deesterification of tert-butyl ester can be achieved by treating with trifluoroacetic acid (TFA) or hydrogen chloride dissolved in ethyl acetate or dioxane overnight.
- TFA trifluoroacetic acid
- the reaction temperature is usually -10 to 20 ° C, preferably -5 to 5 ° C.
- the reaction time varies depending on the starting material used, the acid, the reaction temperature and the like, but is usually 1 to 24 hours, preferably 1 to 15 hours.
- lf for converting the R 1 4 double or R 1 'to R 3 ⁇ for example when R 9 is a group containing at IT force protected
- Amino group is a group containing a Asetoimi Doiruimino groups, amino It can be converted by deprotecting the group and reacting with ethylacetimidate. If the protecting group for the amino group is a Boc group, it is removed simultaneously with tert-butylester by treatment with TFA.
- the Z group can be deprotected by a hydrogenation method.
- the ability to use an angle such as palladium carbon or platinum as the hydrogenation angle is preferably palladium carbon.
- an inert organic solvent that does not cause keratotoxicity can be used.
- alcohols methanol, ethanol, etc.
- ethers eg, THF, etc.
- amides eg, DMF, DMAc, etc.
- Acetic acid or water is used, preferably methanol.
- the reaction is usually carried out at 0 to 50 ° C, preferably at 10 to 30 ° C.
- the reaction time varies depending on the starting materials, the solvent, etc., and is usually 1 hour to 24 hours, preferably 1 hour to 15 hours.
- a commonly used base eg, an inorganic base such as sodium carbonate, carbonated lime, sodium hydroxide, or hydroxylated lime, or a trialkylamine, N -Methylmorpholine, pyridine, organic bases such as N, N-dimethylaminopyridine).
- an inorganic base such as sodium carbonate, carbonated lime, sodium hydroxide, or hydroxylated lime, or a trialkylamine, N -Methylmorpholine, pyridine
- organic bases such as N, N-dimethylaminopyridine
- the reaction solvent is not particularly limited as long as it does not hinder the progress of the reaction and dissolves the raw materials, but amides (eg, DMF, DMAc, etc.), esters (eg, ethyl acetate, etc.), ethers (eg, , Methyl ether, dioxane, etc.), and halogenated hydrocarbons (eg, dichloromethane, chloroform, etc.) and the like, and preferably DMF.
- the reaction ⁇ Jt is usually ⁇ 20 to 50 ° C., preferably ⁇ 5 to 30 ° C.
- the reaction time is generally 5 minutes to 24 hours, preferably 10 minutes to 15 hours.
- the compound of the general formula (XX IX) can be produced by reacting a carboxylic acid of the general formula (XXV III) with a hydroxyl-protected hydroxylamine by a conventional coupling technique.
- a carboxylic acid of the general formula (XXV III) with a hydroxyl-protected hydroxylamine by a conventional coupling technique.
- Examples of the condensing agent to be used include DCC, EDC ⁇ HC1, EEDQ, H0BT ⁇ j, H0NB induction :, HOSu induction, isobutyloxycarbonyl chloride, and monoalkyl ester carbonate induced by reaction with ethyloxycarbonyl chloride.
- the reaction solvent is not particularly limited as long as it does not hinder the progress of the reaction and dissolves the raw materials.
- Amides eg, DMF, DMAc, etc.
- esters eg, ethyl acetate, etc.
- ethers E.g., diethyl ether, dioxane, etc.
- hydrogen and hydrogenated hydrocarbons (e.g., dichloromethane, chloroform, etc.), and preferably DMF power.
- the reaction is usually at -20 to 20 ° C, and preferably at -15 to 0 ° C.
- the reaction time is generally 1 hour to 72 hours, preferably 2 hours to 48 hours.
- R 1 and R 2 are the same as defined above.
- R 1 is a tert-butyl group, a benzyl group, a substituted benzyl group, or a Boc group, particularly preferably a benzyl group, and R 2 is a Boc group or a Z group.
- condensing agent used in this reaction examples include, for example, DCC, EDCHC1, EEDQ, H0BT, H0NB invitation, HOSu invitation, dimethyl isobutyloxycarbonyl, and carbonic acid formed by reaction with ethyl carbonyl chloride.
- Monoalkyl ester derivatives, DPPA and the like are enumerated, preferably EDC ⁇ HC1.
- the reaction solvent is not particularly limited as long as it does not hinder the progress of the reaction and dissolves the raw materials.
- Amides eg, DMF, DMAc, etc.
- esters eg, ethyl acetate, etc.
- ethers For example, dimethyl ether, dioxane, etc.
- hydrogenated carbons eg, dichloromethane, chloroform, etc.
- the reaction temperature is usually -20 to 20 ° C, preferably -15 to 0 ° C.
- the reaction time is generally 1 hour to 24 hours, preferably 2 hours to 15 hours.
- the compound of the general formula (I) can be prepared by removing the protecting group for the hydroxyl group or the amino group of the compound of the formula (VI) or the compound of the general formula (XXIX), or, if desired, by converting R "to R 3 , R 12 to R 4 , R 13 to R 5 , or RM to R 9 .
- the protecting group for the hydroxyl group is a benzyl group and the protecting group for the amino group is a Z group or (C to Z)
- deprotection can be performed simultaneously by the hydrogenation method.
- an angle such as palladium carbon or platinum can be used as the hydrogenation angle, but palladium carbon is preferred.
- an inert organic solvent that does not become horn butterfly venom and can be used such as alcohols (methanol, ethanol, etc.), amides (eg, DMF, DMAc, etc.), acetic acid or Water is used, preferably methanol or acetic acid.
- the reaction is usually from 0 to 100. C, preferably 10 to 50 ° C.
- the reaction time varies depending on the starting material, solvent, reaction and the like used, and is usually 1 hour to 24 hours, preferably 1 hour to 15 hours.
- R 9 is a group containing an amino group protected by R M and R 9 is a group containing an acetimidoyl imino group, deprotect the amino group; It can be converted by reacting with ethyl acetimidate.
- a commonly used base group an inorganic base such as sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, or trialkylamine, N -Methylmorpholine, pyridine, organic bases such as N, N-dimethylaminopyridine) in the presence of acetylacetimidate.
- the reaction solvent is not particularly limited as long as it does not hinder the progress of the reaction and dissolves the raw materials, but amides (eg, DMF, DMAc, etc.), esters (eg, ethyl acetate, etc.), ethers (eg, , Methyl ether, dioxane, etc.), and halogenated hydrocarbons (eg, dichloromethane, chloroform, etc.) and the like, and preferably DMF.
- the reaction is usually at -20 to 50 ° C, preferably at -5 to 30 ° C.
- the reaction time is generally 5 minutes to 24 hours, preferably 10 minutes to 15 hours.
- the reaction product obtained as described above can be easily isolated and purified by ordinary isolation and purification methods, such as extraction with water or an organic solvent, fiber, neutralization, distillation, column chromatography, and recrystallization. Can be isolated.
- the resulting compound is in the form of its solvate or salt (including acid salt) Often, they may be derived from pharmaceutically or pharmaceutically or physiologically acceptable acids or bases.
- These salts include, but are not limited to, the following: salts with inorganic acids such as hydrochloric acid, bromic acid, iodic acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid; ⁇ Depending on r, salts with organic acids such as acetic acid, propionic acid, oxalic acid, succinic acid, citric acid, ascorbic acid, lactic acid, p-toluenesulfonic acid, methanesulfonic acid, fumaric acid, tartaric acid and maleic acid; sodium Salts with alkali metals such as potassium, calcium, magnesium, etc., or salts with metals, and salts with inorganic bases such as ammonium, and organic bases (eg, dialkylamines such as dimethylamine and getylamine
- these compounds (I) may be used in a conventional manner in the form of a salt with a pharmaceutically or physiologically acceptable acid or base, for example, a salt with an inorganic acid such as a hydrochloride, a sulfate or a salt thereof.
- a salt with an inorganic acid such as a hydrochloride, a sulfate or a salt thereof.
- organic acids such as acetate, oxalate, succinate, and maleate
- salts with alkali metals such as sodium and potassium salts
- salts with alkali metals such as calcium salts ⁇ 1 straight metal Can guide you.
- Diseases relating to paper degradation that apply the compounds obtained according to the present invention include Alhaimai, Parkinson's disease, ulcer, ulcer:: ulitis, aphthous ulcer, autoimmune ⁇ ⁇ ashamed (rheumatoid arthritis, clone Disease, autoimmunity, anemia in illness), osteoarthritis, periodontal disease, corneal ulcer, uveitis, ⁇ 7 bullosis (congenital epidermolysis bullosa, acquired epidermolysis bullosa, emergent cutaneous porphyria) , Pemphigus, pemphigus vulgaris), refractory skin ulcers (pressure ulcers, skin ulcers in radiation-treated patients, skin ulcers in diabetic patients, skin ulcers in patients with obstructive arteriosclerosis), osteoporosis, courtt's disease, blood vessels Newborn (associated with cancer growth, lymphoma, ovarian cancer, metastasis and invasion), cachexia, various infections (malaria, he
- the compound (I) and its salts produced by this method are low-toxic and have excellent oral absorption, and strongly inhibit the activity of vertebrate-derived matrix meta-oral proteinase ( ⁇ ) And strongly inhibits the activity of Z or factor-a (1W-a) converting enzyme, and is useful for animals, especially mammals (eg, humans, dogs, puppies, rats, etc.).
- Compound (I) of the present invention and salts thereof are diseases related to vertebrate-derived MMPs and Z or TNF- ⁇ converting enzyme, such as Alzheimer's disease, Parkinson's disease, armitis, ulcerative inflammation, aphthous ulcer, autoimmune diseases (rheumatoid arthritis, Crohn's disease) , Anemia in autoimmune diseases), osteoarthritis, periodontal disease, corneal ulcers, uveitis, @ 7] bullosis (congenital raw epidermolysis bullosa, acquired epidermolysis bullosa acquisita, Cutaneous vorfilinosis, pemphigus, diarrhea Pemphigus), intractable skin ulcers (pressure ulcers, skin ulcers in radiation-treated patients, skin ulcers in diabetic patients, skin ulcers in patients with obstructive arteriosclerosis), osteoporosis, Behcet's disease, angiogenesis (cancer) Lymphoma, ovarian cancer, metastasis and invasion associated with
- N [4- (3,4,4-trimethyl-2,5 dioxo-imidazolidine-tolyl) -KS) -methylcarbamoylbutyl] -N is hydroxy 2 (R or S)-[3- (p -Guanidomethylphenyl) propyl] -3 (R) -Isopropyl succinamide. 1 Acetate
- those containing a phosphono group which may be protected as a functional group thereof are expected to exhibit an activity of inhibiting bone destruction, and are useful for preventing osteoporosis and the like. It is considered promising as Z or Juji U, and is expected to be used in the prevention and / or treatment of diseases related to bone paper disassembly.
- the inhibitory activity of the compound represented by the general formula (1) according to the present invention on human fibroblast-derived collagenase was determined by the method of Y. Murawaki et al. [Journal of Hepatology] , 18, p328-334 (1993)], and stromelysin inhibitory activity derived from human saccharomyces cells is tested by the method of SS Twining [Anal. Biochem, 143, 30 (1984)]. The result of this test will be described later as a test example along with its specific measurement method.
- compound (I) or a salt thereof When used as a medicament, compound (I) or a salt thereof may be administered in any dosage form (including by the injection method or rectal administration) depending on the purpose, such as oral administration, topical administration, or parenteral administration.
- dosage form including by the injection method or rectal administration
- pharmaceutical compositions or formulations eg, powders
- inventive compound alone or in admixture with pharmaceutically acceptable carriers, adjuvants, excipients, excipients and Z or diluents Can be.
- compositions can be formulated according to the usual methods.
- solid dosage forms for oral administration include those described above such as powders, granules, tablets, pills, and capsules.
- the active compound comprises at least one additive such as sucrose, lactose, cellulose sugar, mannitol, maltitol, dextran, starches, agar, alginate, chitin, Chitosans, pectins, tragacanth gums, gum arabic, gelatins, collagens, casein, albumin, synthetic or semi-synthetic polymers can be mixed with glycerides.
- Such dosage forms may also comprise, as usual, further additives, such as inert diluents, lubricants such as magnesium stearate, preservatives such as parabens, sorbic acid and the like. And anti-oxidants such as ascorbic acid, a-tocopherol and cysteine, disintegrants, binders, thickeners, buffering agents, sweetening agents, flavoring agents, perfume agents and the like. Tablets and pills can also be prepared by enteric coating. Typically, tablets and capsules for oral administration use the labeling format for each dose, and can contain the following conventional additives using ordinary means. Tablets can be coated according to methods well known in normal pharmaceutical practice
- fillers such as lactose, sugar, corn starch, canolecium phosphate, sorbitol or glycine;
- tableted lubricants such as magnesium stearate, talc, polyethylene glycol or silica,
- a degrading agent such as potato starch or an acceptable moist chemical such as sodium laurinole sulfate.
- Oral liquid preparations can include, for example, inert diluents commonly used in the art, such as water, and typically include suspensions, solutions, It can be formed in the form of an emulsion, syrup, or elixir, or can be provided as a dry product for reconstitution with water or other suitable MJ ⁇ agent before use.
- inert diluents commonly used in the art, such as water
- suspensions, solutions It can be formed in the form of an emulsion, syrup, or elixir, or can be provided as a dry product for reconstitution with water or other suitable MJ ⁇ agent before use.
- Such liquid preparations include suspensions, for example sorbitol, syrup, methylcellulose, gnorecose syrup, gelatin, hydrogenated fats; emulsifiers, for example lecithin, sorbitan monooleate or acacia; (including edible oils).
- Non-aqueous vehicles for example, flat oil, fractionated coconut oil, oily esters such as glycerin, propylene glycol or ethyl alcohol; preservatives, such as methyl or propyl P-hydroxybenzoate or sorbic acid
- other conventional additives such as, and if necessary, conventional seasonings or coloring agents.
- a single dose for oral administration is about 1 mg to 10 g, preferably containing about 10 mg to 1 of the compound of general formula (I).
- the dosage varies depending on the target disease, symptoms, administration target, administration method, etc., and the appropriate daily dose varies greatly depending on the patient's condition. When administered to mammals, for example, adults, it is 0 per kg of body weight. An appropriate amount of 01-500 mg, especially 0.1-300 mg / kg of body weight, for inner month ⁇ of the compound of formula (I) is appropriate.
- the dosage for a particular patient may depend on age, weight, general health, gender, diet, time of administration, mode of administration, blood flow rate, drug combination, and the condition of the patient being treated at that time. Depending on these and other factors.
- Chemicals for topical application to the skin can be formulated into nightly or suspension of suitably sterilized water or non-aqueous KB agents.
- Additives include preservatives, including bactericidal and antifungal agents such as, for example, buffers such as sodium bisulfite or sodium sodium edetate; mercuric acetate or mercuric nitrate; Thickeners such as hypromelrose are mentioned.
- the dose to be used for topical administration is determined by the size of the area to be treated, and the amount of one dose (one eye) used for eyes is the compound of formula (I), in the range of 0.01 to 100 mg. is there.
- the active ingredient can be administered parenterally using a sterile medium.
- mouth means subcutaneous 3 ⁇ 4 dimension, intravenous i3 ⁇ 4 dimension, intramuscular 3 ⁇ 4! Dimensions, injection within ⁇ ⁇ Or a drip method.
- Formulations for example, sterile aqueous or oily suspensions may be prepared in a manner known in the art using suitable dispersing or wetting agents and suspending agents.
- the sterile injectable preparation may also be a sterile; sterile; overnight solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as an aqueous solution.
- Permissible vehicles or solvents that can be used include water, Ringer's solution, isotonic starvation solution, and the like.
- sterile fixed oils may conventionally be employed as a solvent or suspending medium.
- any bland fixed oil and fatty acid can be used, including natural or synthetic or semi-synthetic fatty oils or fatty acids, and natural or synthetic or semi-synthetic mono-, di- or triglycerides.
- Suppositories for the administration of drugs are composed of the drug and a suitable nonirritating excipient, such as cocoa butter and polyethylene glycols, and a liquid which is solid at room temperature. It can be manufactured by mixing with a substance that melts in the process and releases a drug.
- a suitable nonirritating excipient such as cocoa butter and polyethylene glycols
- the drug can be suspended or dissolved in the excipient.
- Adjuvants such as local anaesthetics, preservatives and buffering agents can be dissolved in the adjuvant.
- the compounds of the invention can be administered orally or by intra-articular measurement of the affected joint.
- the daily dose for a 70 kg mammal is in the range from 0.001 mg to 6 g of the compound of general formula (I).
- the present invention further provides pharmaceutical-acceptable packs (and / or containers or bodies), including one or more containers, filled with one or more of the aforementioned composition components of the present invention, and kits.
- pharmaceutical-acceptable packs and / or containers or bodies
- containers including one or more containers, filled with one or more of the aforementioned composition components of the present invention, and kits.
- Such is a document (document), together with the container (s), in the form indicated by a government agency regulating the manufacture, use or sale of pharmaceuticals or biological products, It may be accompanied by a notice (package) indicating the agency's approval of the manufacture, use or sale of the product for human administration. Difficult case
- Boc tert-butyloxycarbonyl, Bn; benzyl, Me; methyl, C1-Z; 2-chlorobenzyloxycarbonyl, Z: benzyloxycarbonyl,
- Benzyl tert-butylmalonone (24.9 g, 99.6 ol) was dissolved in DMF (60 ml), and iff-potassium tert-butoxide (13.4 g, 120 ml) was added at 0 ° C under iff. Was added little by little.
- the mixture was allowed to stand at room temperature for 1 hour, and again to 0X, and DMF (60 ml) of the compound 16-a (28.4 g, 99.6 mmol) was added dropwise over 1 hour.
- Dissolve 16-b (9.49 g, 20.9 mmol) in DMF (100 ml) and stir at room temperature under stirring at 60% sodium hydride (1.0 g, 25.1 t ol). Was added little by little.
- the wheat was cooled to 0 ° C for 2 hours at room temperature, and cinnamyl bromide (5.35 g, 27.2 mmol) was added little by little, followed by 15 hours at 5 ° C. After distilling off the solvent, Ac0Et (500 ml) was added, and the mixture was washed twice with mu ⁇ IN hydrochloric acid, saturated sodium bicarbonate aqueous solution twice, and saturated saline in this order.
- Trifluoroacetic anhydride (4 ml) was added to 300-carboxy-2 (S) -hydroxy-5-methylhexanoic acid (440 mg 2.31 amino acid 1), and the mixture was stirred at 0 ° C for 4 hours.
- the solvent was distilled off, methanol (4 ml) was added to the residue, and the mixture was stirred at 0 ° C for 2 hours.
- the compound 1 (8.20 g, 20.8 mmol) was dissolved in 4N HC1 (AcOEt solution, 100 ml) under ice-cooling, followed by the same procedure for 45 minutes.
- the reaction solution was concentrated by ffi, Et 2 0 (100 ml) was added to the residue, and the precipitated crystals were collected by filtration and dried under ffi to obtain the title compound as white crystals.
- Dissolve 22-c (2.0 g, 4.31 country ol) in methanol (40 ml), add 5% palladium carbon (50% wet, 1.0 g), and add 3.5% at room temperature with flowing hydrogen. Time was intense. After the angular medium was filtered off, the solvent was distilled off. The obtained residue was dissolved in DMF (40 ml), and the mixture was heated to 0 ° C, and TEA (1.93 ml, 13.8 ol) and ethyl ethyl imideto hydrochloride (577 mg, 4.53 ol) were added.
- the obtained solid was dissolved in DMF (300 ml) and dissolved at ⁇ 15 ° C. after 1
- the reaction mixture was added dropwise to water (2 L) at room temperature for 15 hours, and the precipitated crystals were collected by filtration.
- the obtained crystals were washed with 1N hydrochloric acid, 103 ⁇ 4Na 2 CO 3 water, water and Et 20 in that order, and dried under reduced pressure to obtain white crystals (39.2 g, 95%).
- ⁇ -NR (CDC1 3 + CD 3 0D) (5 pin; 0.5-1.0 ( Keio ⁇ m, CH (CH 3) 2 + CO- CH- CH 3), 1.2-1.5 (2H, m, CH2-CH ( CH 3 ) 2 ), 2.0 and 2.34 (1H each, m, CH-C0 x 2), 2.73 (3H, m, NH-CHs), 2.98 and 3.19 (1H each, m, 0 6 0 4 3 ⁇ 4), 3 59 (1H, m, NH-CH-C0), 4.63 (1H, m, NH), 4.86 (2H, m, 0-CH ⁇ -Ph), 7.13 (1H, m, NH), 7.3-7.6 ( 9H, m, aromatic-H) c) N a- [4- (Hydroxyamino) -2 (R) -isobutyl-3 (RS) -methylzasuccinyl] -4'-aminomethyl-refene Lulan
- the solvent was distilled off at -15 ° C for 1 hour and at room temperature for 15 hours.
- AcOEt was (200 ml) was added, saturated ⁇ *, 1N hydrochloric acid, saturated NaHCO 3 water reservoir night, was separated washed twice each in the order of saturated A3 ⁇ 47.
- the obtained residue was dissolved in acetic acid (100 ml), and after adding 5% palladium on carbon (50% wet, 3.0 g), the mixture was violently lightned at room temperature for 1.5 hours while flowing hydrogen. After filtering off the butterflies, the acetic acid was distilled off under reduced pressure, and the resulting residue was dissolved in water and dried by drying to obtain the title compound (2.55 g, 32%) as a white solid.
- the obtained purified product was dissolved in acetic acid (20 ml), added with 5% palladium on carbon (50% wet, 300 mg), and vigorously stirred at room temperature for 2 hours while flowing hydrogen. After filtering off the corner butterfly, AcOEt (20 ml) was added to the residue obtained by evaporating acetic acid, and the precipitated solid was collected by filtration to obtain the title compound (250 mg, 64%) as a white solid.
- the compound 96 was hydrolyzed to obtain the title compound as a white solid.
- the compound 102 was hydrolyzed to give the title compound as a white solid.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU15066/99A AU753017B2 (en) | 1997-12-12 | 1998-12-11 | Novel metalloproteinase inhibitors |
BR9813554-6A BR9813554A (pt) | 1997-12-12 | 1998-12-11 | Composto, uso do mesmo, processo para produzi-lo, composição farmacêutica ou veterinária, e, inibidor de metaloproteinase |
CA002313649A CA2313649A1 (en) | 1997-12-12 | 1998-12-11 | Novel metalloproteinase inhibitors |
KR1020007006430A KR20010033069A (ko) | 1997-12-12 | 1998-12-11 | 신규한 메탈로프로테이나제 억제제 |
EP98959181A EP1038864A1 (en) | 1997-12-12 | 1998-12-11 | Novel metalloproteinase inhibitors |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP36236497 | 1997-12-12 | ||
JP9/362364 | 1997-12-12 | ||
JP10/218676 | 1998-07-17 | ||
JP21867698 | 1998-07-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999031052A1 true WO1999031052A1 (fr) | 1999-06-24 |
Family
ID=26522692
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/005620 WO1999031052A1 (fr) | 1997-12-12 | 1998-12-11 | Nouveaux inhibiteurs de metalloproteinases |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1038864A1 (ja) |
KR (1) | KR20010033069A (ja) |
CN (1) | CN1284060A (ja) |
AU (1) | AU753017B2 (ja) |
BR (1) | BR9813554A (ja) |
CA (1) | CA2313649A1 (ja) |
RU (1) | RU2200154C2 (ja) |
WO (1) | WO1999031052A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001055327A (ja) * | 1999-06-11 | 2001-02-27 | Fuji Chemical Industries Ltd | 新規なヒドロキサム酸誘導体を含む医薬 |
WO2002006227A1 (fr) * | 2000-07-18 | 2002-01-24 | Chugai Seiyaku Kabushiki Kaisha | Inhibiteurs de la metalloprotease matricielle |
US6541661B1 (en) | 1999-11-23 | 2003-04-01 | Methylgene, Inc. | Inhibitors of histone deacetylase |
US8063104B2 (en) | 2004-11-12 | 2011-11-22 | Ucl Business Plc | Guanidine derivatives as inhibitors of DDAH |
WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
US10973920B2 (en) | 2014-06-30 | 2021-04-13 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
US11021514B2 (en) | 2016-06-01 | 2021-06-01 | Athira Pharma, Inc. | Compounds |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008156701A2 (en) * | 2007-06-13 | 2008-12-24 | The Brigham And Women's Hospital, Inc. | Hydroxamate inhibitors of insulin-degrading enzyme and uses thereof |
BR112015014391B1 (pt) * | 2012-12-18 | 2020-11-03 | The Secretary Of State For Health | compostos antimicrobianos, seus métodos de preparação, composição e sal farmaceuticamente aceitável dos mesmos |
CN103435514B (zh) * | 2013-08-01 | 2015-11-25 | 中国人民解放军军事医学科学院毒物药物研究所 | 基质金属蛋白酶抑制剂及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56158746A (en) * | 1980-04-11 | 1981-12-07 | Wellcome Found | Pharmaceutical amide |
JPS57116043A (en) * | 1981-01-12 | 1982-07-19 | Tetsuo Suami | New nitrosourea derivative and its preparation |
JPH04352757A (ja) * | 1991-02-01 | 1992-12-07 | F Hoffmann La Roche Ag | アミノ酸誘導体 |
-
1998
- 1998-12-11 AU AU15066/99A patent/AU753017B2/en not_active Ceased
- 1998-12-11 CN CN98813374A patent/CN1284060A/zh active Pending
- 1998-12-11 BR BR9813554-6A patent/BR9813554A/pt not_active IP Right Cessation
- 1998-12-11 RU RU2000118320/04A patent/RU2200154C2/ru not_active IP Right Cessation
- 1998-12-11 KR KR1020007006430A patent/KR20010033069A/ko not_active Application Discontinuation
- 1998-12-11 CA CA002313649A patent/CA2313649A1/en not_active Abandoned
- 1998-12-11 EP EP98959181A patent/EP1038864A1/en not_active Withdrawn
- 1998-12-11 WO PCT/JP1998/005620 patent/WO1999031052A1/ja not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS56158746A (en) * | 1980-04-11 | 1981-12-07 | Wellcome Found | Pharmaceutical amide |
JPS57116043A (en) * | 1981-01-12 | 1982-07-19 | Tetsuo Suami | New nitrosourea derivative and its preparation |
JPH04352757A (ja) * | 1991-02-01 | 1992-12-07 | F Hoffmann La Roche Ag | アミノ酸誘導体 |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001055327A (ja) * | 1999-06-11 | 2001-02-27 | Fuji Chemical Industries Ltd | 新規なヒドロキサム酸誘導体を含む医薬 |
US6541661B1 (en) | 1999-11-23 | 2003-04-01 | Methylgene, Inc. | Inhibitors of histone deacetylase |
USRE39850E1 (en) | 1999-11-23 | 2007-09-18 | Methylgene, Inc. | Inhibitors of histone deacetylase |
USRE43343E1 (en) | 1999-11-23 | 2012-05-01 | Methylgene Inc. | Inhibitors of histone deacetylase |
WO2002006227A1 (fr) * | 2000-07-18 | 2002-01-24 | Chugai Seiyaku Kabushiki Kaisha | Inhibiteurs de la metalloprotease matricielle |
US8063104B2 (en) | 2004-11-12 | 2011-11-22 | Ucl Business Plc | Guanidine derivatives as inhibitors of DDAH |
US10973920B2 (en) | 2014-06-30 | 2021-04-13 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
US11021514B2 (en) | 2016-06-01 | 2021-06-01 | Athira Pharma, Inc. | Compounds |
WO2020070239A1 (en) | 2018-10-04 | 2020-04-09 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Also Published As
Publication number | Publication date |
---|---|
RU2200154C2 (ru) | 2003-03-10 |
BR9813554A (pt) | 2001-07-24 |
AU753017B2 (en) | 2002-10-03 |
KR20010033069A (ko) | 2001-04-25 |
CN1284060A (zh) | 2001-02-14 |
CA2313649A1 (en) | 1999-06-24 |
EP1038864A1 (en) | 2000-09-27 |
AU1506699A (en) | 1999-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69432614T2 (de) | Alkohol und Aldehyde Derivate als Cathepsin L Inhibitore und als Inhibitore der Knochenresorption | |
JP2843921B2 (ja) | P物質拮抗剤としてのベンジルオキシキヌクリジン | |
EP0320118B1 (en) | Peptides with collagenase inhibiting activity | |
JP2602181B2 (ja) | 消炎薬としてのペプチジル4−アミノ−2,2−ジフルオロ−3−オクソ−1,6−ヘキサン二酸誘導体 | |
EP0434365A2 (en) | HIV protease inhibitors useful for the treatment of aids | |
JP2004115531A (ja) | 置換環状アミンメタロプロテアーゼ阻害剤 | |
CS20192A3 (en) | Amino acid derivatives, process of their preparation and use | |
US20080125375A1 (en) | Protease inhibitors | |
EP0839149B1 (fr) | Derives de la galanthamine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant | |
AU642046B2 (en) | N-(2-alkyl-3-mercaptoglutaryl)-amino-diaza cycloalkanone derivatives and their use as collagenase inhibitors | |
JP3156794B2 (ja) | 高水溶性メタロプロテイナーゼ阻害剤 | |
WO1999031052A1 (fr) | Nouveaux inhibiteurs de metalloproteinases | |
US5254682A (en) | Cyclic renin inhibitors containing 3(S)-amino-4-cyclohexyl-2(R)-hydroxy-butanoic acid or 4-cyclo-hexyl-(2R, 3S)-dihydroxybutanoic acid or related analogs | |
JPH04210966A (ja) | 新規化合物、その製法及びそれを含む医薬組成物 | |
US20050159474A1 (en) | Chemical compounds | |
JPWO2003033507A1 (ja) | ベンジルマロン酸誘導体およびそれを含有するプロテアソーム阻害薬 | |
US4587250A (en) | Thiazaspirane derivatives, process for their preparation, and medicaments | |
US5151437A (en) | Benzofurancarboxamides having basic substituents and therapeutic agents containing the same | |
JPH05506651A (ja) | 新規化合物 | |
WO2000069812A1 (fr) | Nouveaux dérivés d'acide hydroxamique | |
JP2001055327A (ja) | 新規なヒドロキサム酸誘導体を含む医薬 | |
JP2001031637A (ja) | 新規なヒドロキサム酸誘導体 | |
JP2000086611A (ja) | 新規なメタロプロテイナ―ゼ阻害剤 | |
JPH07196598A (ja) | ヒドロキサム酸誘導体およびそれを有効成分とする医薬組成物 | |
JP3048643B2 (ja) | 5,7−ジヒドロ−3−[2−{1−ベンジルピペリジン−4−イル}エチル]−6H−ピロロ−[4,5−f]−1,2−ベンズイソオキサゾール−6−オンの製造方法及び中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 98813374.1 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) |
Free format text: (EXCEPT GD) |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2313649 Country of ref document: CA Ref document number: 2313649 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15066/99 Country of ref document: AU Ref document number: 1998959181 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020007006430 Country of ref document: KR Ref document number: 09581402 Country of ref document: US Ref document number: PA/A/2000/005808 Country of ref document: MX |
|
WWP | Wipo information: published in national office |
Ref document number: 1998959181 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007006430 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 15066/99 Country of ref document: AU |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998959181 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007006430 Country of ref document: KR |